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Abstract 
Hyperuricemia could be caused by the overproduction or the underexcretion of urate. 
Urate is a product of an enzyme, xanthine oxidase (XOD). XOD participates in the 
purine degradation pathway, converting xanthine or hypoxanthine to urate, and urate 
is then excreted through the kidney. Medical treatments now available to treat 
hyperuricemia include the use of urate oxidase, uricosuric agents and XOD inhibitors. 
These methods of treatments may sometimes produce adverse side effects. Therefore, 
development of new and safer methods for the treatment of hyperuricemia is needed. 
Chinese medicinal materials (CMM) constitute a rich source of potential drugs, as 
they have demonstrated clinical efficacy and less side effects. The objective of this 
project is to search for XOD inhibitory compounds from the CMM: aloe, ginger and 
rhubarb. The chemical components of these herbs studied in the present investigation 
include 6-gingerol, aloe-emodin, barbaloin, chrysophanol, deoxyrhapontin, rhapontin 
and rhein. Deoxyrhapontin was found to possess reversible XOD inhibitory effect, 
with a mixed type mode of inhibition. The other compounds were found to be without 
positive effects. Moreover, compounds with XOD inhibitory effects could reduce the 
blood level of urate and alleviate hyperuricemia. If the compounds also possess 
antioxidant abilities, they might be able to alleviate atherosclerosis by lowering the • 
susceptibility of blood components towards oxidative stress. A number of 
antioxidative assays on red blood cell (RBC) and RBC membrane were thus 
performed. They include AAPH-induced hemolysis inhibition assay, RBC membrane 
lipid peroxidation inhibition assay, RBC membrane Ca^^-ATPase and Na+/K+-ATPase 
protection assays, and RBC membrane sulfhydryl group protection assay. Among the 
test compounds, 6-gingerol was demonstrated to possess positive effect in the AAPH-
i 
induced hemolysis inhibition assay and RBC membrane lipid peroxidation inhibition 
assay. Rhapontin was demonstrated to possess positive effect in the AAPH-induced 
hemolysis inhibition assay, RBC membrane lipid peroxidation inhibition assay and 
RBC membrane Na+/K+-ATPase protection assay. Barbaloin was demonstrated to 
exhibit efficient protection in all of the assays except Na+/K+-ATPase assay. Apart 
from RBC, low-density lipoprotein (LDL) is another target of oxidants. Engulfment 
of oxidized LDL by macrophages would lead to accumulation of plaques in arteries, 
resulting in atherosclerosis. Lipid peroxidation inhibition assays of LDL were 
performed to evaluate the antioxidative abilities of the compounds towards LDL. 6-
Gingerol, barbaloin and rhapontin were demonstrated to exhibit positive effects in 
these assays. The significance of these biologically active compounds from CMM is 
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Chapter 1 Introduction 
1.1 Reactive oxygen species 
Stable chemical molecules consist of paired electrons. However, there are other 
molecules that hold one or more unpaired electrons. They are the free radicals which 
are chemically very reactive. They may possess electropositive, neutral or 
electronegative charge, depending on the reaction conditions (Olinescu and Smith, 
2002). Free radicals are produced during metabolic reactions, and many of them are 
important reaction intermediates. Oxygen is essential to life due to its key role in 
energy metabolism, but it is also harmful to biological molecules owing to its 
tendency to generate reactive oxygen species (ROS). In human, ROS can be produced 
intracellularly and extracellularly. 
1.1.1 Intracellular sources of ROS 
ROS including superoxide radicals, hydrogen peroxide and hydroxyl radicals are by-
products of respiration in aerobes. Intracellular ROS are mainly produced in 
mitochondria. The amount of ROS produced differs among tissues due to the 
differences in metabolic processes taking place (Olinescu and Smith, 2002). For the 
complete reduction of molecular oxygen into water, four electrons are being added to 
the ROS intermediates one at a time (Olinescu and Smith, 2002). Although the 
mitochondrial electron transport chain (ETC) is highly efficient in reducing molecular 
1 
i 
oxygen, 2-3% of the electrons leak out daily causing the release of ROS from the 
mitochondria (Rice-Evans et cd.’ 1995). 
+ e" + e" + e" + e' 
O2 > O2' > H2O2 f 'OH > H2O 
2H+ OH" H+ 
In the membrane-bound peroxisomes, hydrogen peroxide is produced for fatty acid 
oxidation in mitochondria (Olinescu and Smith, 2002). Sometimes, hydrogen 
peroxide may leak out from mitochondria or peroxisomes as it is lipid soluble (Marks 
et aL, 1996). 
1.1.2 Extracellular sources of ROS 
Extracellular ROS are produced by macrophages, neutrophils and eosinophils as a 
response to bacterial invasion (Marks et al., 1996). The ROS produced by these cells 
include superoxide anion radicals, hydrogen peroxide, hydroxyl radicals and 
hypochlorous acid. These ROS constitute a major part in the bodies' defence against 
invading bacteria by their abilities to kill the engulfed bacteria through oxidizing their 
membranes and other cellular components (Marks et al., 1996). 
1.1.3 Superoxide anion radicals 
Superoxide anion radicals (O2'') are believed to be the first ROS produced in the ETC 
as molecular oxygen accepts an electron. 
02 + e- > 02*" 
They are also produced in some enzyme-catalyzed reactions, e.g. xanthine oxidase 




Evans et al, 1995). It is not particularly reactive compared to other ROS, but it is the 
precursor of other ROS such as hydroperoxyl radical (HOO*), hydrogen peroxide 
( H 2 O 2 ) and hydroxyl radical (.OH). Therefore, removal of superoxide radicals by the 
enzyme superoxide dismutase (SOD) is considered to be an important primary 
antioxidant defence against ROS damage by virtually all aerobes from bacteria to 
I 1 
multicellular organisms (Marks et al, 1996). 
1.1.4 Hydrogen peroxide 
Peroxide ion (O2 ') is produced during the second step of the reduction of molecular 
oxygen in the ETC when a second electron is added to superoxide radicals (Olinescu 
and Smith, 2002). 
02.- + e- >02^" 
Under physiological conditions, the ion normally forms a stable compound, H2O2, 
which is a non-free radical form of oxygen since all of its electrons are paired 
(Olinescu and Smith, 2002). � 
O22- + 2H+ >H202 
H2O2 is lipid soluble, so it is able to diffuse through cell membrane (Marks et al” 
1996). It is also produced by the SOD-catalyzed dismutation of superoxide radicals. 
The equation is mentioned in section 1.2.2. 
1.1.5 Hydroxyl radicals 
Hydroxyl radicals (*0H) are the most powerful ROS. They can be produced from H t; 





( V •+ H2O2 > 02 + OH- + 'OH 
They can also be produced by disintegration of hydrogen peroxide through the Fenton 
reaction (Olinescu and Smith, 2002): 
Fe2+ + H2O2 > Fe3+ + OK + .OH 
They form peroxides on reacting with organic substances such as proteins and lipids. 
1.1.6 Singlet oxygen 
Singlet oxygen (^02) is another powerful ROS which is a non-free radical (Olinescu 
and Smith, 2002). It is believed to be produced by photosensitization reactions in the 
eyes and may also be produced by neutrophils. It is able to react with organic 
substances such as polyunsaturated fatty acids to form peroxides (Olinescu and Smith, 
2002). 
1.1.7 Peroxyl radicals and peroxides 
Peroxyl radicals and peroxides are formed during a series of chain reactions in 
compounds with unsaturated carbon backbones. The process of formation includes 
initiation, propagation and termination. Initiation of free radical production can be 
achieved by homolysis, metabolism, enzymatic reactions, photolysis, radiolysis, redox 
reactions and free radicals in nature (Roberfroid and Calderon, 1995). In these 
reactions, an electron is lost from a compound to form a free radical. The chain 
reaction is then propagated by the reaction of the free radicals with the substrates 
I 
present. The substrates can be carbohydrates, protein or lipids in living organisms. [ 
During propagation, atom transfer, electron transfer and addition reaction can take 




‘place. The chain reaction is terminated when there is linking of radicals, radical 
scavenging by antioxidants or when radicals are depleted (Larson, 1997). 
1.1.8 Damage of cellular structures by ROS 
As ROS are reactive, they can target on biological molecules and cause damage on 
cellular structures. When lipid becomes the target of ROS, lipid peroxidation results. 
Chain reaction can be initiated in the presence of metal ions such as copper and iron, 
as they can enhance the production of hydroxyl radicals. Lipid radical (L*) is formed 
due to free radical attack of polyunsaturated lipid (LH) (Marks et al., 1996): 
LH + .OH > L' + H2O 
Lipid peroxyl radicals (LOO*) and lipid peroxide (LOOH) are formed due to 
propagation of the chain reaction (Marks et al., 1996): 
L. + 02 > L 0 0 ' 
LOO' + LH > LOOH + L* 
Malondialdehyde (MDA) is produced as a result of lipid degradation. MDA in blood 
or urine can be determined to indicate the degree of free radical injury during 
oxidative stress. The chain reaction continues until terminated by a termination 
reaction (Marks et al., 1996): 
LOO. + L. > LOOH + LH 
When proteins become the target of ROS, a series of reactions occur which finally 
lead to protein degradation. These include protein carbonyl formation, scission or 
cross-linking of polypeptides, oxidation of sulfhydryl group, and dysfunction and 
denaturation of proteins. When DNA becomes the target, DNA mutation and DNA 
breakage occurs. Degradation of DNA bases into purines and pyrimidines may result. 
5 
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1.2 Antioxidative defence in the body 
Human body is equipped with a series of antioxidant defence mechanisms to 
counteract the destructive effects of ROS. These defence mechanisms could be in the 
form of proteins, enzymes or compounds. 
1.2.1 Antioxidant proteins 
Certain plasma proteins can be regarded as antioxidant proteins. Some of them such 
as albumin react with ROS by sacrificing themselves to spare other blood components 
(Miller et al., 1995). Other antioxidant proteins such as serum transferrin and 
cytosolic ferritin chelate transition metal ions (Fe^ "^ ) which take part in the Fenton 
reaction (Camejo et al” 1998). Plasma also contains haptoglobin which binds 
hemoglobin and hemopexin which binds hemin (Miller et al,, 1996). 
1.2.2 Antioxidant enzymes 
Antioxidant enzymes remove ROS or convert them into less toxic forms. They 
include SOD, catalase and glutathione peroxidase (GSH-Px) (Knight, 2000). 
Superoxide radicals synthesized in the mitochondria are removed by mitochondrial 
Mn-SOD (Marks et al” 1996). Cytosolic Cu,Zn-SOD removes superoxide radicals in 
the cytosol and extracellular Cu,Zn-SOD helps to attenuate oxidative damage of brain 
and lung (Bowler et al” 2002). Universal occurrence of SOD in the body reflects the 
importance of superoxide radicals as the primary ROS. 
SOD 





GSH-Px and catalase are present inside the cell to remove H2O2, as H2O2 is the 
precursor of the highly reactive hydroxyl radicals (Marks et al., 1996). Catalase is 
mainly associated with peroxisomes where a large amount of H2O2 is produced. GSH-
Px is found in the cytosol, on membranes and other cellular compartments. It has been 
suggested that GSH-Px is capable of removing very low level of H2O2，but it has low 
capacity due to the requirement of reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) to regenerate reduced glutathione (GSH). In contrast, catalase 
has high capacity in removing H2O2 produced by drug oxidation or fatty acid 
oxidation, but it is insensitive to low H2O2 concentrations (Rice-Evans et al., 1995). 
Catalase 
2H2O2 > 2H2O + O2 
GSH-Px 
2GSH + H2O2 > GSSG + 2H2O 
Intracellular GSH level is maintained by glutathione reductase (GSSG-Rd) for the 
normal activity of GSH-Px. The reduction of oxidized glutathione (GSSG) by GSSG-
Rd requires reducing equivalents from NADPH: 
GSSG-Rd 
GSSG + NADPH +H+ > 2GSH + NADP+ 
1.2.3 Antioxidant compounds 
Vitamin E, vitamin C and carotenoids are low-molecular-weight antioxidant 
compounds with in vivo effects, and dietary supplementation is required. Urate, 
bilirubin, GSH and ubiquinol can be produced in vivo (Knight, 2000). Among the 
antioxidants, vitamin E, vitamin C, GSH and urate will be described. 
7 
1.2.3.1 Vitamin E 
The lipid soluble vitamin E (Vit E or tocopherols) serves as the main antioxidant to 
protect against lipid peroxidation in which a-tocopherol is the most biologically active 
form in animals. Its ability to form stable tocopheryl radical (Vit E*) enables it to 
scavenge free radicals and to stop propagation of chain reactions. Tocopheryl quinone 
(Vit Eox) is formed eventually by further oxidation (Marks et al., 1996). Its water 
soluble form, trolox, is used as positive control in most assays. 
L* + Vit E >LH + Vit E* 
Vit E* + L' > LH + Vit Eox 
OH 
H s C - ' ^ Y I 
Figure 1.1 Chemical structure of vitamin E. 
CHs 
CHg 
Figure 1.2 Chemical structure of trolox. 
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1.2.3.2 Vitamin C 
Vitamin C (or L-ascorbic acid) is hydrophilic in nature. It is able to react with 
superoxide and hydroxyl radicals to form ascorbyl radical and eventually becomes 
dehydro-L-ascorbic acid upon complete oxidation (Marks et al., 1996). It can 
regenerate vitamin E from its oxidized forms (Marks et al” 1996). 
r 
HO OH 
Figure 1.3 Chemical structure of vitamin C. 
1.2.3.3 Glutathione 
GSH is an intracellular antioxidant. It is a tripeptide which is made up of glutamate, 
cysteine and glycine (7-Glu-Cys-Gly). The GSH pool is compartmentalized in 




Urate is the reaction product of XOD in the purine degradation pathway. It possesses 
antioxidative ability as it accepts electrons readily from ROS. It scavenges hydroxyl 
radicals and peroxynitrite and reacts with nitric oxide (Kirschbaum, 2001). It also has 
transition metal ion chelating ability as it inhibits metal-induced oxidative destruction 
by binding with them without being oxidized itself (Rice-Evans et al” 1995). Urate 
can protect red blood cell (RBC) membrane against lipid peroxidation and inhibit 
9 
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hemolysis (Ames et al., 1981). Therefore, urate may have the ability to defend against 
aging, a condition hypothesized to be caused by the accumulation of free radical-
induced damage. In fact, a high serum urate level is believed to contribute to the 
longevity of human as compared to other mammals (Knight, 2000). As urate is the 
product of purine degradation, therefore the purine metabolic pathway can be 
considered as one of the defence mechanisms against ROS attack. 
1.2.3.4.1 Purine metabolism 
Purine metabolism consists of two major pathways: de novo purine synthesis and the 
purine salvage pathway (Moriwaki et al., 1999). For the de novo pathway, 5'-
phosphoribosyl-1 -pyrophosphate (PRPP) is produced from ATP and ribose-5-
phophate (R-5-P) in the initial step. R-5-P is the product of the pentose phosphate 
pathway which is essential to the antioxidation mechanism of RBC. 
Phosphoribosylamine is formed from PRPP and L-glutamine. Consequently, inosine 
monophosphate(IMP) is produced for purine ring formation. Adenosine 
monophosphate(AMP), IMP, xanthosine monophosphate(XMP) and guanosine 
monophosphate(GMP) are dephosphorylated into adenosine, inosine, xanthosine and 
guanosine, respectively. Inosine and guanosine are then cleaved into hypoxanthine 
and guanine, respectively. Hypoxanthine is oxidized into xanthine and subsequently 
to urate by XOD. Urate is the end product of purine de novo pathway in human and 
primates. In other mammals and lower vertebrates, urate is further degraded into 
allantoin by urate oxidase, an enzyme that is defective in human. For the purine 
salvage pathway, hypoxanthine and guanine are recycled to IMP and GMP 
respectively, and adenine is recycled to AMP (Figure 1.4). 
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Figure 1.4 Purine ribonucleotide biosynthesis, interconversion and degradation 
pathways. Abbreviations: AK, adenosine kinase; APRT, adenine 
phosphoribosyltransferase; HGPRT, hypoxanthine-guanine phosphoribosyltransferase; 
5'-ND, 5'-nucleotidase; ADA, adenosine deaminase; PNP, purine nucleoside 
phosphorylase; XOD, xanthine oxidase; IMP, inosine monophosphate; AMP, 
adenosine monophosphate; AMP-S, adenoyl-succinate; XMP, xanthosine 
monophosphate; GMP, guanosine monophosphate (Moriwaki et al” 1999). 
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1.2.3.4.2 Xanthine oxidase 
Under normal physiology, XOD should be in its original form: xanthine 
dehydrogenase (XDH). Normally, oxidized nicotinamide adenine dinucleotide (NAD+) 
is the substrate in the reaction catalyzed by XDH. The enzyme, XOD (EC 1.1.3.22)，is 
a dimer, each of them contains one flavin adenine dinucleotide (FAD), one 
molybdenum cofactor and two iron-sulfur centers (Moriwaki et al, 1999). FAD is a 
cofactor which accepts electrons during the enzymatic reaction (Olinescu and Smith, 
2002). XOD participates in the final steps of purine degradation pathway, which takes 
place mainly in the liver. It converts hypoxanthine to xanthine, and further converts 
xanthine to urate. It is in the XDH form in liver. 
XDH XDH 
Hypoxanthine > Xanthine > Urate 
As XOD is an oxidoreductase, the reduced FAD cofactor has to be reoxidized in order 
to complete its catalytic cycle. If molecular oxygen is used instead of NAD+ for the 
reoxidation of FAD, superoxide radicals and H2O2 are produced (Silverman, 2000). 
XOD 
Hypoxanthine + H2O + lOi > Xanthine + 20广 + 2H+ > H2O2 + O2 
XOD 
Xanthine + H2O + lOi > Urate + 209*' + 2H+ > H2O2 + O2 
1.2.4 Oxidative stress and antioxidant defence mechanisms in RBC 
RBC are highly differentiated cells which do not have any nuclei, mitochondria and 
other cellular organelles (Surgenor, 1974). They carry respiratory gases between the 
lungs and other tissues in the body. Since protein synthesis is virtually absent in 
mature RBC, replacement of damaged structures is impossible. This renders RBC 
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vulnerable to attack by endogenous and exogenous ROS. One of the endogenous ROS 
sources for RBC comes from the hemoglobin they carry. About 2-3% of hemoglobin 
is constantly converted into methemoglobin by molecular oxygen and superoxide 
radicals are produced during the process: 
Hb(Fe-II) + O2 > O2' - + Hb(Fe-III) 
In addition, the heme group in hemoglobin also contributes to ROS generation. Heme 
is composed of a porphyrin ring which is associated with an iron atom. The porphyrin 
ring is made up of four pyrrole rings linked with methenyl bondings (Marks et al.’ 
1996). During the degradation of RBC under oxidative stress (Takahashi et al., 2004)， 
heme is released from hemoglobin which is then oxidized to become hemin. 
Me Me 
H 2 C = C H ^ C H 2 — C H 2 - C O 2 " 
M e • C H 2 _ C H 2 _ C 0 2 -
H 2 C = C H Me 
• 2 H + 
Figure 1.5 Chemical structure of heme. 
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Me Me 
H2 C = CH CH 2 - CH 2 - CO 2 _ 
CH 2 - CH 2 - CO 2 _ 
H 2 C = CH Me 
• 2 H + 
Figure 1.6 Chemical structure of hemin. 
Hemin is an oxidant. It enhances peroxyl radical formation and propagates chain 
reaction in lipid peroxidation. Hemin also generates hydroxyl radicals in the presence 
of H2O2 in a Fenton-type reaction. When excess heme is present under oxidative 
stress, it is able to attack RBC and induces hemolysis. Methemoglobin, with a 
trivalent iron ion like hemin, can act as an oxidant in a similar way. 
Due to the potential hazardous effect of heme, free heme is being removed by the 
body once it is formed. This is accomplished by the consecutive actions of heme 
oxygenase(HO) and ferritin. During heme degradation, heme is oxidized to biliverdin 
by HO with the released of Fe^ "^  ions which are subsequently chelated by ferritin. 
Biliverdin is further converted into bilirubin and excreted (Marks et al., 1996). 
Bilirubin is an antioxidant in vivo. It associates with albumin and produces 
antioxidant effect at low concentrations (Mireles et al” 1999). 
1 4 
In order to defend against ROS attack, RBC have developed some special antioxidant 
defence mechanisms. Like other cells, they possess SOD, catalase and GSH-Px as 
their primary antioxidant armaments. 
The energy metabolism in RBC plays a major role in its antioxidant defence. Apart 
from the generation of energy, it provides reducing equivalents to maintain cellular 
antioxidant potential. For example, reduced nicotinamide adenine dinucleotide 
(NADH) produced from glycolysis is essential to reduce methemoglobin to 
hemoglobin by the action of methemoglobin reductase. NADPH produced from the 
pentose phosphate pathway is essential to complete the GSH antioxidant mechanism 
by keeping GSH in the reduced form through the action of GSSG-Rd (Marks et al” 
1996). 
The GSH antioxidant mechanism is particularly important to RBC. RBC have GSH-
Px which removes hydrogen peroxide and lipid peroxides (Marks et al.’ 1996). 
Coupling of GSSG reduction is performed by GSSG-Rd. The thiol group in GSH also 
serves as a ligand for the heme-associated iron ion (Shviro and Shaklai, 1987). GSH 
competes for hemin with the membrane, thus lowering the damaging effect of hemin 
towards RBC (Shviro and Shaklai, 1987). 
RBC membrane is a phospholipid bilayer with proteins embedded. Among the 
membrane proteins, ATPases help to keep the cell intact by maintaining ion 
homeostasis. Two of the ATPases are the Na+/K+-ATPase and the Ca^"'-ATPase. Their 
3-dimentional structures have been compared (Jorgensen et al., 2003)，and is found to 
be similar. 
1 5 
1.2.5 Oxidative stress and antioxidant defence mechanisms in LDL 
Low density lipoprotein (LDL) is a class of serum lipoprotein with a phospholipid 
monolayer and an apoprotein BlOO (Alberts et al., 1994). It is responsible for the 
transport of cholesterol, cholesterylesters and triglycerides to tissues and regulates de 
novo cholesterol synthesis. The transported substances are the main constituents of 
cellular membrane and they enter target cells by receptor-mediated endocytosis 
(Stryer, 1995). LDL in the circulation are susceptible to oxidation by molecular 
oxygen and other pro-oxidants. Each LDL contains several molecules of vitamin E 
and some LDL also contain ubiquinol for antioxidation purpose (Stocker, 1993). 
Ubiquinol can be considered as an antioxidant in human (Knight, 2000). When LDL 
is attacked by free radicals, vitamin E on LDL scavenges the radicals and is in turn 
converted to a-tocopheroxyl radical. In order to protect LDL from peroxidation, 
vitamin E has to be regenerated. This is done by the presence of ubiquinol in LDL and 
vitamin C in human plasma (Stocker, 1993). 
1.3 Human diseases originated from pro-oxidant conditions 
J 
ROS can be generated massively if there are defects in the metabolism or under 
pathological conditions. When the amount of ROS exceeds the antioxidant capacity of 
the body, cells and tissues will become vulnerable to free radical attack, a condition 




Blood LDL undergoes continual oxidation. If it remains in the circulation for an 
extended period of time due to insufficient LDL uptake, the oxidized form of LDL 
will accumulate and injure cells on the vessel lumen. This condition attracts 
monocytes. The monocytes may become foam cells if they engulf too much oxidized 
LDL (Marks et al” 1996). These foam cells together could form plaques on arterial 
walls, thus narrowing the vessels' diameter and minimizing the vessels' flexibility. 
This eventually causes atherosclerosis (Marks et al., 1996). If the event happens in 
coronary arteries, cardiovascular disease and heart attack may result. 
1.3.2 Ischemia / reperfusion injury 
XOD has been suggested to be involved in the pathogenesis of post-ischemic 
reperfusion injury such as during organ transplantation. This is due to the generation 
of ROS (Moriwaki et al., 1999). XOD usually exists in cells in the form of XDH. 
XDH is converted into XOD by the proteolytic action of cytosolic calcium-dependent 
protease which is probably activated due to the increase in intracellular calcium ion 
concentration during ischemia (Engerson et al.’ 1987; Fernandez et al., 2004). In 
addition, release of adenosine also increases due to extensive hydrolysis of ATP. The 
adenosine is converted into inosine then into hypoxanthine. Therefore, XOD 
constitutes an important source of ROS during reperfusion since the oxidation of 
xanthine and hypoxanthine by XOD leads to the generation of massive amount of 
superoxide radicals (Engerson et al” 1987). The organs that may be injured by 
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ischemia/reperfusion include brain, heart, gastrointestinal tract and kidney (Canas, 
1999). 
1.3.3 Glucose-6-phosphate dehydrogenase deficiency 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inborn disease in which 
NADPH is unavailable for GSSG-Rd's action. GSSG formed by GSH-Px cannot be 
reduced back to GSH in the absence of NADPH. The RBC become vulnerable to 
oxidative stress. Cross-linking of hemoglobin results in the formation of Heinz bodies 
on RBC membrane. Heinz body is an aggregate of cross-linked hemoglobin. This 
results in the decrease in deformability of RBC. The shear stress exerted on the RBC 
during passage through the capillaries renders the RBC to undergo hemolysis (Marks 
et al, 1996). 
1.3.4 DNA mutation 
^ I I 
Transition metal ions such as Fe and Cu may bind to DNA non-specifically. The 
highly reactive hydroxyl radicals will be produced by the Fenton reaction in the 
presence of H2O2 (Marks et al., 1996). The hydroxyl radicals in turn cause DNA 
strand breakage or mutation. ROS may also interact with transcription factors and 
influence their normal function. If mutation occurs in mitochondrial DNA, the 
components of ETC may become defective. The output of energy may decline and 
electron leakage may increase which would result in the release of more ROS. This 
mechanism has been hypothesized to be involved in the process of aging (Knight, 
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2000). If DNA mutation happens in somatic cells, the ordinary cellular function and 
regulation will be affected. This will lead to cancer. 
1.3.5 Other pro-oxidant state related diseases 
Other diseases that are associated with oxidative stress include diabetes, asthma, 
cystic fibrosis, cataract, hematologic disorders, acute renal failure, stroke, Parkinson's 
disease, cerebrovascular disorder, Alzheimer's dementia and psoriasis (Rice-Evans et 
a/., 1995; Marks et al., 1996; Olinescu and Smith, 2002). 
1.4 Hyperuricemia and gout: diseases originated from an extreme 
antioxidant condition 
Hyperuricemia is a hallmark of gout which is caused by elevation in urate synthesis or 
reduction in urate excretion, or both. Prolonged hyperuricemic condition enhances 
accumulation of urate, leading to the formation of sodium urate crystals. When the 
urate deposits in joints and kidneys, gout results. The disease can be classified into 
primary gout and secondary gout. The former is a congenital disease, whereas the 
latter is non-congenital and is common in male. Symptoms of gout include swelling 
and inflammation of joints, malfunctioning of kidneys, chills and fever. Primary gout 
is caused by disorder in purine metabolism, which is contributed by genetic 
abnormality which leads to functional deficiency of one or more enzymes in the 
purine pathway (Lehninger, 2000). 
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There are several conditions for primary gout. Some patients may have a partial 
deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This is an 
enzyme catalyzing the synthesis of IMP and GMP in the salvage pathway from 
hypoxanthine and guanine respectively. 
HGPRT 
Hypoxanthine + PRPP > IMP + PPi 
HGPRT 
Guanine + PRPP > GMP + PPi 
In the case of complete HGPRT deficiency, Lesch-Nyhan Syndrome results. 
Deficiency of HGPRT reduces GMP and IMP synthesis and elevates PRPP level. This 
enhances purine biosynthesis by the de novo pathway, thus the formation of 5-
phosphoribosyl-1 -amine increases. Another condition is that some patients may have 
hyperactive PRPP synthetase with impaired allosteric regulation. This will lead to 
excess PRPP production. Similar problem arises which finally lead to hyperuricemia. 
Regarding secondary gout, it can be caused by different non-congenital factors. The 
reasons for elevated urate production may include rich purine meal, obesity and 
hypertriglyceridemia (Harris et al” 1999). The reasons for reduced urate excretion 
may include the use of diuretic drugs, renal dysfunction and hypothyroidism (Harris 
et al., 1999). Prevalence of gout from 1983 to 1985 according to the National Health 
Survey in USA is 1.36% in men and 0.64% in women. The incident rate has increased 
three folds since 1969 (Harris et al., 1999). 
1.4.1 Inhibition of XOD as a treatment method for hyperuricemia 
One of the treatment methods for gout is to inhibit XOD. By inhibiting the enzyme, 
xanthine and hypoxanthine become the products of the purine metabolic pathway. 
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They are more soluble in water compared to urate, and therefore they do not form 
crystals and can be excreted more easily (Lehninger, 2000). 
Allopurinol has been used to treat gout extensively. It is an analog of hypoxanthine. 
When compared to hypoxanthine, the position of one of the N atoms is exchanged 
with one of the C atoms of allopurinol. 
0 0 
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Hypoxanthine Allopurinol 
Figure 1.7 Chemical structures of hypoxanthine and allopurinol. 
However, there are a number of adverse side effects associated with allopurinol 
administration. Allopurinol is a very powerful irreversible inhibitor of XOD. Urate 
production is inhibited, and hypoxanthine and xanthine levels rise. On the one hand, 
this leaves out an important antioxidant. The reduction in serum urate level would 
reduce the antioxidant capacity of the body (Waring et al” 1991; Nieto et al, 2000). 
On the other hand, xanthinuria may result. The dramatic increase in hypoxanthine and 
xanthine levels may lead to xanthine precipitation and results in the development of 
kidney stones (Kenney, 1991; Stryer, 1995). Moreover, there are a number of adverse 
side effects associated with allopurinol. Symptoms including rashes, fever, vomiting, 
eosinophilia, nausea, diarrhea, toxic epidermal necrolysis, acute vasculitis, renal 
dysfunction and massive hepatic necrosis have been reported (Wortmann, 2002; 
Horiuchi et al” 2000; Kong, Cai, et al., 2000). In severe situations, some patient may 
2 1 
develop allopurinol hypersensitivity syndrome, which could be lethal (Kong, Zhang, 
et al., 2000). 
1.4.2 Relationship between ROS injury and hyperuricemia 
XOD plays significant roles in purine metabolism and ischemia-reperfusion injury. 
This is due to its reaction products urate and superoxide radicals, which are 
antioxidant and ROS respectively. Normal serum urate levels for male and female are 
lower than 7mg/dL and lower than 6mg/dL respectively (Chang et al., 2001), which • 
are close to the solubility limit of urate in human blood (7mg/dL at 37°C) (Stryer, 
1995). Although the high serum urate level in human increases the danger of 
hyperuricemia, it may contribute to the protection of blood components from ROS 
attack since urate is an antioxidant (Nieto et al., 2000; Ames et al” 1981). 
Epidemiological studies have shown a positive correlation between hyperuricemia 
and atherosclerosis (Lin et al., 2004; Aucamp et al” 1997). The reason for this 
phenomenon is still controversial. One of the studies suggested that urate level 
increases in atherosclerotic patients may be due to a compensatory antioxidant 
defence mechanism (Nieto et al,’ 2000). The correlation between hyperuricemia and 
atherosclerosis leads to the research direction of finding potential drugs with XOD 
inhibitory and antioxidant effects (Aucamp et al., 1997). If a compound is found to 
have both XOD inhibitory and antioxidative ability, it would be ideal (Shigematsu et 
al; 2003; Tsutsumi et al, 2004). Compounds with both effects might be able to 
inhibit urate production on the one hand, and replenishing the antioxidative ability on 
the other. 
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1.5 Antioxidants in human nutrition 
Regarding the prevalence of ROS-derived diseases, supplementation with antioxidant 
vitamins is a possible preventive measure. However, human are exposed to higher 
oxidative stress due to new diseases and environmental pollution. Therefore, 
application of natural products contributes another possible alternative, since these 
products contain antioxidants with potency comparable to that of traditional vitamins, 
and they are abundantly available with fewer side effects. Examples of natural 
antioxidant sources include green tea, cruciferous vegetables and many herbs. 
1.6 Chinese medicinal therapeutics 
Numerous natural products have been evaluated for their effects towards different 
diseases. Supplementation with traditional antioxidants and vitamins which aids in the 
prevention of free radical derived diseases become insufficient to cope with many 
new diseases. Regarding the side effects generated by the current drugs, it is 
necessary to explore new drugs with higher efficacy and potential. Chinese medicinal 
material (CMM) has become a new source of such explorations (Lee, 2000). Among 
thousands of CMM, a number of them have been applied in prescriptions since 
ancient times for curing diseases which are currently identified to be caused by ROS 
and hyperuricemia. 
Gout is classified as bizheng (搏症）in traditional Chinese medicine (TCM) where bi 
stands for obstruction. Bizheng results from the attack of wind, cold, dampness and 
heat in which the flow of qi and blood through channels and meridians is hindered. 
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This generates pain and numbness to muscles, bones, tendons and joints. Bizheng in 
chronic condition may cause blood stasis or phlegm-turbidity (Wu and Fisher, 1944). 
In The Yellow Emperor 's Canon of Internal Medicine (黄帝內'經),the cause of bi was 
described: 
“As wind, cold and dampness attack in turn or strike in alliance, bi will occur." 
V風寒濕三氣襲至、合而爲痹也。J 
In The Synopsis of the Golden Chamber, Zhongfeng Lijie Chapter (金匱要略，中風 
歷節篇)，symptoms of gout including painful joints and swollen limbs have been 
reported. Gout is called tongfeng (痛風）(which means the pain spreads like a wind), 
lijie (歷節）(which means over the joint) or lijie wind (歷節風）(which means the pain 
spreads over the joint in an acute manner). In accordance to the TCM theory, the 
clinical symptoms of gout can be identified as follows. They include wind-cold-
dampness obstruction which means acute arthritis, obstruction of meridians by 
phlegm-turbidity which means ankylosis and stranguria, kidney qi deficiency which 
means edema and dizziness, qi and yin deficiency which means kidney failure (Kong, 
Cai，et al.’ 2000). 
From previous research work carried out by my former labmates (Kong, Cai, et al., 
2000), 122 herbal extracts from ancient Chinese prescription for treatment of diseases 
related to gout were screened. Several extracts including an extract of rhubarb were 
found to possess positive effects on XOD inhibition. However, the chemical 
components which are responsible for the effect and the reaction mechanisms remain 
unclear. In the present study, the XOD inhibitory effects of selected chemical 
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compounds from rhubarb and structurally similar compound from aloe were 
investigated. A phenolic compound from ginger with phenolic structures similar to the 
stilbenes tested in the present investigation was also studied. 
1.6.1 Rhubarb 
Rhubarb is the common name for the Rheum species, which belongs to the family of 
Polygonaceae. Examples of Rheum species include Rheum palmatum L., R. 
tanguticum Maxim., R. officinale Baill.，R. coreanum Nakai and R. undulatum L. 
(Matsuda et al., 2001). Rhubarb is distributed in western and northwestern China, 
Korea, other parts of Asia and Europe. Its rhizomes and roots are applied for 
medicinal purposes (WHO, 1999). In The Divine Farmer 's Classic of Materia Medica 
(神農本草經),the application of rhubarb was described: 
“It is bitter in taste and cold in nature. It is mainly used for the discharge of blood 
stasis in the cold-heat blood blockage condition.” 
「味苦寒。主下疲血，血閉寒熱。」 
It has been used for curing chronic renal failure and blood stagnation syndrome which 
are related to the clinical conditions of gout (Kong, Cai, et al., 2000; Matsuda et al., 
2001). This herb has also been reported to possess antimicrobial, antitumor, anti-
inflammatory, hemostatic and hypercholesterolemic lowering activities. Almost half 
of the Rheum species found possess drug value (Xiao et al., 1984). 
Anthraquinone derivatives and stilbenes are the major constituents isolated from the 
rhizomes and roots of Rheum. The anthraquinones aloe-emodin and rhein have been 
reported to be good scavengers of hydroxyl radicals (Yuan and Gao，1997; Yen et al., 
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2000). Rhapontin, a stilbene commonly found in Rheum species, has been suggested 
to be a good agent for decreasing cholesterol level and anti-allergy (Li and Ye, 1981; 
Kim et al.，2000). In this study, several compounds from Rheum including aloe-
emodin (1,8-dihydroxy-3-(hydroxymethyl)anthraquinone), chrysophanol (1,8-
dihydroxy-3-methylanthraquinone), rhein (4,5-dihydroxyanthraquinone-2-carboxylic 
acid), deoxyrhapontin (deoxyrhaponticin or 3,5-dihydroxy-4‘-methoxystilbene 3-/3-0-
glucoside) and rhapontin (rhaponticin or 3,3',5-trihydroxy-4'-methoxystilbene 3-/5-D-
glucoside) were tested in order to investigate their inhibitory effect on XOD and their 
antioxidative ability. 
1.6.2 Aloe 
Aloe belongs to the family of Liliaceae. Aloe is the common name and genus name of 
all Aloe species. There are about 300 Aloe species. Examples of medicinal aloe 
include Aloe vera (L.) Burrri f.，A. ferox Mill, and A. vera L. var. chinensis Berger. 
Most Aloe species are originated from Africa, they can also be found in Asia and 
America. Their leaves are applied for medicinal purposes. Aloe can be used to 
enhance wound healing, improve skin quality, decelerate skin aging, treat occasional 
constipation (WHO, 1999)，increase urine production due to its uricosuric ability 
(Yagi et al., 2002). Aloe contains anthraquinones and their derivatives. Barbaloin 
(1,8-dihydroxy-10-(i8-D-glucopyranosyl)-3-(hydroxymethyl)-9( 1 OH)-anthracenone or 
aloin A) is the major constituent (WHO, 1999). 
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1.6.3 Ginger 
Zingiber officinale Roscoe belongs to the family of Zingiberaceae. Its common name 
is ginger. This herb is originated from south-east Asia and found in Africa, China and 
India. Its rhizomes are well-known for its spicy taste and have been used in different 
nations both as spices and medicines. Ginger has been used in TCM for thousands of 
years to induce perspiration and to calm nausea (WHO, 1999). It has also been used in 
several prescriptions of bizheng such as Fang-feng-tang, Gui-zhi-shao-yao-zhi-mu-
tang, Yi-yi-ren-tang and Zhi-gan-cao-tang (Wu and Fisher, 1944). Other usages 
include enhancing flu healing and to treat cataract, bile stone "formation, 
atherosclerosis, and rheumatoid arthritis (Aeschbach et al.’ 1994). Ginger contains 
zingiberene, gingerols, shogoals and their derivatives as its major ingredients (WHO, 
1999). 6-Gingerol is the major pungent constituent in ginger oils extracted from the 
rhizomes (Aeschbach et al., 1994). 
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Figure 1.10 Chemical structures of anthraquinones that were tested in the 
present study. 
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1.6.4 Objectives of the project 
1. Do the herbs that have been applied for curing hyperuricemia and gout-related 
diesases in ancient China possess XOD inhibitory effects? 
2. Do the herbs protect RBC and its constituents against oxidative stress? 
3. What mechanisms do the herbs exert protection on RBC and its constituents? 
4. Can the herbs prevent LDL oxidation which is the major cause of 
atherosclerosis? 
5. Do the herbs possess both XOD inhibitory effect and antioxidative effect? 
6. What is the structure-activity relationship of the active compounds? 
1.6.5 Strategies applied to achieve the objectives of the present project 
A number of assays were performed to study the effects of the components in order to 
identify potential antidote for human diseases with aberrant antioxidant and pro-
oxidant level. XOD inhibitory assay was done to study the hypouricemic actions of 
the compounds. Antioxidant assays were also performed to evaluate the compounds' 
ability in alleviating pro-oxidant situations. RBC assays aim to reveal the compounds' 
protective ability on two important biomolecules, lipids and proteins, since RBC 
membrane possesses typical human cell membrane structure and is easy to obtain 
(Albert et al., 1994). Activity assays for ATPases and protein sulfliydryl group 
protection assay are used to study the degree of protein damage by ROS, and 
thiobarbituric acid (TBA) assay is used for the determination of lipid peroxidation. 
Moreover, LDL assays were carried out to assess the compounds' potential in 
preventing atherosclerosis. 
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Chapter 2 Materials and methods 
In this chapter, the methods of the assays are described in detail. The order that 
reagents were added into the assay mixture is the order that they are listed in the 
procedure. The listed concentrations of the reagents are the final concentrations. 
Reagents used were of analytical grade. 
2.1 XOD inhibition assay 
The enzyme XOD used in this study was purchased from Roche Diagnostics isolated 
from bovine milk. All other reagents used were of analytical grade. The assay was 
performed according to a standard method previously established in our laboratory 
(Kong, Zhang, et al” 2000). 
2.1.1 Assay development 
Prior to the observation of compounds' inhibitory effect on the enzyme, the 
concentrations of enzyme and substrate were determined, so that their optimal 
concentrations were used. A fixed enzyme concentration was reacted with various 
substrate concentrations to determine the saturating substrate concentration. This is 
important as saturating substrate concentration indicates the maximum reaction rate at 
that particular enzyme concentration. A fixed substrate concentration was used with 
various enzyme concentrations to ensure linearity of the assay under the assay 
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conditions. After that, the optimal reaction condition was obtained, at which the 
potential inhibitors could be tested. 
2.1.2 Dose-dependent study 
The activity of XOD was assayed by reacting the enzyme with xanthine under aerobic 
condition (Kong, Zhang, et al., 2000). The assay procedures for XOD are as follows. 
The assay was performed in a final volume of 1ml containing 80mM sodium 
pyrophosphate buffer (pH 7.5), the test compound dissolved in DMSO initially and 
0.089U/ml XOD were mixed and incubated for 10 min in a quartz cuvette at 25°C. 
Then, the reaction was started by adding xanthine (final concentration = 0.12mM) and 
increase in absorbance due to urate production was monitored spectrophotometrically 
at 295nm. The final concentration of DMSO in the assay was 5% at which the assay 
was not affected. Allopurinol was used as a positive control in the assay. 
2.1.3 Reversibility of the enzyme inhibition 
There are two main types of enzyme inhibition, reversible and irreversible. For the 
former type, it is further divided into several different kinds. They are competitive, 
non-competitive, uncompetitive and mixed. In reversible inhibition, the inhibitory 
effect exerted on XOD by the compounds can be reversed, meaning that the activity 
of XOD can regain its original activity after the removal of the inhibitor. The mode of 
reversible enzyme inhibition could then be assessed by the Lineweaver-Burk plot. On 
the other hand, irreversible inhibitor differs from reversible inhibitor that the 
irreversible one forms covalent bond or very tight binding with the enzyme. This 
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renders the enzyme inactive, and the activity of the enzyme can no longer resume its 
original activity again. 
The procedures were the same as in section 2.1.1，except that the enzyme was 
incubated with inhibitor at high concentration for 10 min. The mixture was then 
diluted with assay buffer just before the beginning of reaction, so that the final 
concentrations of the inhibitor, enzyme and substrate were the same as that in the 
dose-dependent experiment. The DMSO concentration in the assay was kept at 5% 
(before and after dilution). 
2.1.4 Lineweaver-Burk plot 
Lineweaver-Burk plot was conducted to find out the mode of inhibition of the test 
compound, whether it is competitive, non-competitive, uncompetitive or mixed type 
inhibitor. The procedures were the same as in section 2.1.1，except that the assays 
were carried out in the absence and presence of the test compound and the 
concentration of the substrate, xanthine, varied. 
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2.2 Lipid peroxidation inhibition assay of mouse liver microsomes 
The lipid peroxidation of mouse liver microsome was produced using the Fe^ "^ -
ascorbate system (Zheng and Zheng, 1992; Basaga et al., 1997) with some 
modifications. 
2.2.1 Preparation of mouse liver microsomes 
BALB/c mice were sacrificed by decapitation. Livers were excised and rinsed twice 
with 0.9% saline at 4°C. All subsequent preparative procedures were carried out at 
4°C unless otherwise specified. Livers were then homogenized in 0.15M KCl. The 
amount of KCl added to liver was 3ml/g. The homogenate was centrifuged at 10，000g 
for 20 min at 4°C. After that, the supernatant was retained and centrifuged at 
lOOjOOOg for 1 h at 4°C. The supernatant was discarded. The pellet was resuspended 
with KCl. The stock was stored at -20°C after determination of protein concentration. 
2.2.2 Basis of assay 
This assay works on the principle that the Fe -ascorbate system generates free 
radical-mediated lipid peroxidation of the liver microsomal preparation. 
Trichloroacetic acid (TCA) is added for protein precipitation after incubation to stop 
further reaction. MDA, the product of the lipid peroxidation, forms complexes with 
TBA. The absorbance of the pink color adduct could be monitored at 532nm. 
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2.2.3 Assay procedures 
The assay was performed in a final volume of 1ml containing phosphate buffered 
saline (PBS) (pH 7.4)，50fi\ of the test compound, 0.4mg/ml mice liver microsomes, 
O.OlmM FeSCU and O.lmM ascorbic acid. The mixture was incubated for 1 h at 30°C. 
When incubation was completed, 1ml of 20% TCA and 1.5ml of 0.8% TBA were 
added to each sample to terminate the reaction. The mixture was boiled for 20 min at 
100°C. After that, it was centrifuged at 3000g for 5 min. The absorbance of the 
supernatant was measured at 532nm. Net absorbance was calculated by subtraction 
between the samples and their own blanks. The degree of lipid peroxidation for each 
sample was expressed in terms of a percentage of the drug-free control. Trolox was 
used as a positive control. The percentage of control was calculated according to the 
following formula: 
% of control = A532 / A532' x 100% 
where: 
A532 = net absorbance of sample 
A532' = net absorbance of control 
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2.3 AAPH-induced hemolysis inhibition assay 
The assay was adopted from the AAPH-induced hemolysis system (Jimenez et al., 
2000) with some modifications. 
2.3.1 Preparation of RBC 
Blood samples from Sprague-Dawley rats were obtained from the Laboratory Animal 
Service Center of the Chinese University of Hong Kong. About 10ml of rat blood 
collected in heparinized tubes was centrifuged at 1500g for 10 min at 4°C. After the 
plasma with white blood cell (WBC) and platelets were removed, the RBC were then 
washed with 0.15M NaCl and centrifuged at 1500g for 10 min at 4°C. This procedure 
was repeated for two more times. In the last wash, the centrifugal speed was lowered 
to lOOOg. After saline was removed, a 20% suspension of the RBC was prepared by 
adding PBS. 
2.3.2 Basis of assay 
This assay works on the principle that 2,2'-azobis (2-ainidinopropane) dihydrochloride 
(AAPH) could generate peroxyl radicals which attack RBC in vitro. Antioxidant 
compounds could thus protect the red cells from this hemolytic action of AAPH. 
3 6 
2.2.3 Assay procedures 
For each sample, the final volume is 1ml containing 500/^ 1 RBC preparation, 250jLtl of 
the test compound dissolved initially in DMSO then diluted with PBS, and lOOmM 
AAPH. The final DMSO concentration in the 1ml mixture was 2.5% at which 
concentration there was minimal effect on the RBC. All samples were incubated at 
37°C for 3 h with gentle agitation. When incubation was completed, 0.1ml of the 
reaction mixture was diluted with 0.9ml PBS, and another 0.1ml of the same reaction 
mixture was diluted with 0.9ml distilled water (DW). All the samples were mixed 
well and centrifuged at 1500g for 10 min at 4°C. From each sample, 200jLil was 
transferred to a 96-well plate for measurement of absorbance at 540nm. Vitamin C 
and trolox were used as positive controls in the assay. Percentage of RBC lysed for 
each sample was calculated according to the following equation: 
% of RBC lysed = A540 in PBS / A540 in DW x 100% 
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2.4 Lipid peroxidation inhibition assay of RBC membrane 
The lipid peroxidation assay of RBC membrane was performed using the tert-
butylhydroperoxide (/BHP)/hemin as the ROS generation system (Rice-Evans et al.’ 
1991; Yokode and Kita, 1988; Zuckerman and Bryan, 1996) with some modifications. 
2.4.1 Preparation of RBC membrane 
Blood collection 
The RBC membrane was prepared according to a reported method (Matteucci et al.’ 
1995) with some modifications. Approximately 90ml rabbit blood was provided by 
the Laboratory Animal Service Center of the Chinese University of Hong Kong on 
each experimental day. The blood was collected in tubes with 60mM EDTA in saline 
as anticoagulant (bloodianticoagulant = 9:1 v/v). 
RBC washing 
Blood was centrifuged at 200g for 10 min at 20°C. The supernatant containing the 
plasma and WBC was removed. RBC was transferred from the Falcon tube to a 
250ml Nalgene centrifuge bottle, and was then resuspended in Buffer 1 in a ratio of 
cell:buffer = 1:10 by volume. The mixture was centrifuged at 1320g for 5 min at 4°C， 
and the supernatant was removed. The above washing step was repeated twice. After 
the last washing, 175ml Buffer 2 was added after removing the supernatant. The 
mixture was shaken vigorously for 5 min, and kept on ice afterwards. It was 
centrifuged at 1320g for 5 min at 4°C. Hemolysate was transferred to a beaker, and 
the pellet discarded. 
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RBC membrane purification 
The hemolysate was centrifuged at 25000g for 20 min at 4°C. The supernatant was 
removed and the pellet was resuspended with 175ml Buffer 2. It was centrifuged at 
25000g for 20 min at 4 � C and the pellet was resuspended with 175ml Buffer 3. The 
mixture was centrifuged at 25000g for 20 min at 4°C and its pellet was resuspended 
with 175 ml Buffer 3. It was centrifuged at 25000g for 20 min at 4°C and the pellet 
was resuspended with 175ml Buffer 4. The mixture was centrifuged at 25000g for 
20 min at 4°C and its pellet was resuspended in Buffer 4. Finally, RBC membrane in 
all centrifuge bottle were combined and homogenized with a syringe several times on 
ice. The stock was pipetted into 1.5ml microfUge tubes and stored at -80°C. 
Buffers 
Buffer 1: 0.15M NaCl 
Buffer 2: O.OIM Tris-HCl buffer with ImM EDTA，pH 7.6 
Buffer 3: O.OIM Hepes-NaOH buffer with ImM EDTA, pH 7.6 
Buffer 4: O.OIM Hepes-NaOH buffer, pH 7.6 
2.4.2 Basis of assay 
This assay works on the principle that hemin catalyses the formation of peroxyl 
radicals from fBHP. The peroxyl radicals then initiate lipid peroxidation of the RBC 
membrane. TCA is added for protein precipitation to stop further reaction. MDA, the 
product of lipid peroxidation, forms complexes with TBA. The fluorescence of TBA 
reactive substance (TBARS) is measured using a fluorometer with an excitation 
wavelength at 515mn and an emission wavelength at 553nm. 
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2.2.3 Assay procedures 
The assay was performed in a final volume of 1ml containing PBS (pH 7.4), 50jLtl of 
the test compound, 0.05mg/ml RBC membrane, O.SmM /BHP and l.SjuM hemin. The 
mixture was incubated at 37°C for 4 h. After incubation, 1ml of 20% TCA was added 
and mixed well. Then, 1ml of 0.8% TBA was added and mixed well. The mixture was 
heated for 1 h at 95°C. It was then centrifuged at 3000g for 5 min at 4°C. The 
supernatant was transferred to another test-tube. Then, 3ml of butan-l-ol was added 
and the mixture was vortexed vigorously for about 10 times. The mixture was 
centrifuged at 3000g for 5 min at 4°C and the top layer was removed for fluorescence 
measurement. The extent of RBC membrane oxidation was measured using an 
excitation wavelength of 515nm and an emission wavelength of 553nm. Net 
absorbance was calculated by subtraction between the samples and their own blanks. 
The degree of lipid peroxidation for each sample was expressed in terms of a 
percentage of the drug-free control. Trolox was used as the positive control. The 
percentage of control was calculated by the following formula: 
% of control = F / F i x 100% 
where: 
F = net fluorescent unit of sample 
Fi = net fluorescent unit of control 
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2.5 ATPase protection assay 
The ATPase protection assay was based on the rBHP / hemin inhibition system (Al-
Jobore and Roufogalis, 1981; Kallner, 1975; Reinila et al., 1982; Watanabe et al,, 
1988) with some modifications. 
2.5.1 Preparation of RBC membrane 
The procedure was the same as described in section 2.4.1. 
2.5.2 Preparation of malachite green (MG) reagent 
A hundred and forty milliliter of 3.53% ammonium molybdate was added to 300ml 
DW. Sixty milliliter of concentrated HCl was then added with stirring. Malachite 
green base (O.lg) was dissolved in the mixture. After 1 h or above, when 
sedimentation of precipitate was completed, the solution was filtered through a glass 
fiber membrane and stored in the dark. 
2.5.3 Basis of assay 
Peroxyl radicals were generated through the rBHP/hemin system. The radicals would 
attack the ATPases and rendered them inactive. I f the compound showed positive 
results in this assay, it might be able to inhibit the inactivation of ATPases. The active 
ATPases would be able to hydrolyse ATP to ADP, with the production of inorganic 
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phosphate (Pi). Pi reacts with MG to give a green-colored complex whose absorbance 
could be read spectrophotometrically at 650nm. 
2.5.4 Assay procedure 
The assay was performed in a final volume of 800/^ 1 containing 400jLtl of 50mM 
Hepes buffer (pH 7.4) and lOO/zl each of the test compound, RBC membrane, ^BHP 
and hemin. The mixture was incubated in a 1.5ml microfuge tube for 4 h at 37°C with 
gentle agitation. The mixture was centrifuged at 20,000g for 5 min at 4°C. The 
supernatant was discarded and the pellet was kept on ice. RBC membrane was 
resuspended in 450jLtl of assay buffer with 0.01% Triton X-100 and incubated at 37°C 
on a dry bath. After 10 min, SOjLtl of lOmM ATP was added. A 50/xl of sample was 
aliquoted for Pj determination. After 10 min, another SOjul sample was aliquoted from 
the same mixture again for Pi determination. The amounts of Pi in the samples were 
determined by absorbance measurement at 650nm after incubation for 30 min with 
1ml of MG reagent and 450jLtl of 1% polyvinyl alcohol (PVA). The absorbance 
readings were compared against a preconstructed calibration curve using K H 2 P O 4 . 
The amount of Pi in the sample released by ATPase activity within a defined period 
was calculated by subtracting the aliquoted sample with zero-time incubation from the 
one with 10 min incubation for each assay. The activities of Ca^^-ATPase and 
Na+/K+-ATPase expressed as nmole Pi/mg/min were calculated according to section 
2.5.5 and 2.5.6. 
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2.5.5 Determination of ATPase activities 
Determination of Ca^^-ATPase activity 
Assay conditions'. 
The final concentrations of RBC membrane, tBR? and hemin were O.Smg/ml, 0.5mM 
and 2jLiM respectively. 
Calculations'. 
Activity with Ca^ "^  or w/o Ca〗. 
=([Pi at 10 min] - [Pi at 0 min]) x 0.5 x 1000 x (0.3 x 0.8)'^  x 10'^  
Net activity = activity with Ca2+ - activity w/o Ca^^  
Determination of Na+/K+-ATPase activity 
Assay conditions: 
The final concentrations of RBC membrane, ^BHP and hemin were Img/ml, 0.5mM 
and 1.5/xM respectively. 
Calculations: 
Activity with K+ or w/o K+ 
=([Pi at 10 min] - [Pi at 0 min]) x 0.5 x 1000 x (1 x 0.8)"^  x 10"^  
Net activity = activity with K+ - activity w/o K+ 
2.5.6 Assay buffers 
• Buffer 1 (w/o K+ and Ca:,: 
o 30mM imidazole-HCl, pH 7.4 
o 0.1 mM imidazole-EGTA 
o 6mM MgCh 
o 50mM NaCl 
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• Buffer 2 (with K+): 
o 30mM imidazole-HCl, pH 7.4 
o O.lmM imidazole-EGTA 
o 6mM MgCb 
o SOmM NaCl 
o SmM KCl 
• Buffer 3 (with Ca "^"): 
o 30mM imidazole-HCl, pH 7.4 
o 0.1 mM imidazole-EGTA 
o 6mM MgCl2 
o SOmM NaCl 
o 0.3mM CaCl2 
2.6 Sulfhydryl group protection assay 
The sulfhydryl group protection assay of RBC membrane was performed using 
hemin/rBHP as the ROS generation system (Haest et al., 1978; Liu et a l , 1992; 
Soszynski and Bartosz, 1997; Xia et al., 1999) with some modifications. 
2.6.1 Preparation of RBC membrane 
The procedure was the same as described in section 2.4.1. 
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2.6.2 Basis of assay 
Peroxyl radicals were generated through the ^BHP/hemin system, oxidizing the 
sulfhydryl group in the membrane protein. I f the test compound possessed protective 
effect, it would be able to inhibit the oxidation of protein sulfhydryl groups. The intact 
sulfhydryl groups react with 5,5' -dithiobis(2-nitrobenzoic acid) (DTNB) to yield a 
yellow-colored complex, which could be detected spectrophotometrically at 412nm. 
2.6.3 Assay procedures 
The assay was performed in a final volume of SOO/xl containing 400jLtl of SOmM 
Hepes buffer (pH 7.4)，lOO/xl of the test compound, 0.3mg/ml RBC membrane, 
O.SmM rBHP and lOjLtM hemin. The mixture was incubated in a 1.5ml microfuge tube 
for 4 h at 37°C with gentle agitation. The mixture was centrifuged at 20，000g for 
5 min at 4°C. The supernatant was discarded and the pellet was kept on ice. Then, 
SOOjLtl ofO.lM phosphate buffer (pH 7.4) and lOOjul of 4mg/ml EDTA were added and 
vortexed. After that, 500/xl of 10% w/v sodium dodecyl sulfate (SDS) was added and 
mixed well. Finally, lOO/zl of ImM DTNB was added and mixed well. Color was 
allowed to develop for 15 min at 25°C and absorbance was measured at 412nm. Net 
absorbance was yielded by subtracting the absorbance of blank (containing an 
equivalent concentration of protein) from the absorbance of sample. The amount of 
free sulfhydryl groups in protein was determined from a standard curve constructed 
with known amounts of GSH. 
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2.7 Lipid peroxidation inhibition assay of LDL by the AAPH method 
LDL used in this study was purchased from Calbiochem. Al l other reagents used were 
of analytical grade. Lipid peroxidation of LDL was produced by AAPH oxidation 
(Rice-Evans et al； 1991; Yokode and Kita, 1988; Zuckerman and Bryan, 1996) with 
some modifications. 
2.7.1 Basis of assay 
This assay works on the principle that AAPH generates peroxyl radicals and induces 
lipid peroxidation of LDL. TCA is added for protein precipitation to stop further 
reaction. MDA, the product of lipid peroxidation, forms complexes with TBA. The 
fluorescence of TEARS is measured using a fluorometer with an excitation 
wavelength at 515nm and an emission wavelength at 553nin. 
2.7.2 Assay procedures 
The assay was performed in a final volume of 1ml containing PBS (pH 7.4)，O.SmM 
EDTA, 50jul of the test compound, O.lmg/ml LDL and 20mM AAPH. The mixture 
was incubated at 37°C for 2 h. The procedures for the determination of lipid 
peroxidation products in the RBC membrane were performed as mentioned in section 
2.4.3. Trolox was used as a positive control. 
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2.8 Lipid peroxidation inhibition assay of LDL by the hemin method 
LDL used in this study was purchased from Calbiochem. All other reagents used were 
of analytical grade. Lipid peroxidation of LDL was produced in the presence of hemin 
(Rice-Evans et al” 1991; Yokode and Kita, 1988; Zuckerman and Bryan, 1996) with 
some modifications. 
2.8.1 Basis of assay 
This assay works on the principle that hemin propagates lipid peroxidation with the 
aid of existing lipid peroxides. TCA is added for protein precipitation to stop further 
reaction. MDA, the product of lipid peroxidation, forms complexes with TBA. The 
fluorescence of TEARS is measured using a fluorometer with an excitation 
wavelength at 515nm and an emission wavelength at 553nm. 
2.8.2 Assay procedures 
The assay was performed in a final volume of 1ml containing PBS (pH 7.4)，50/xl of 
the test compound, O.lmg/ml LDL and 1/zM hemin. The mixture was incubated at 
37°C for 2 h. The procedures for the determination of lipid peroxidation products in 
the RBC membrane were performed as mentioned in section 2.4.3. Trolox was used 
as a positive control. 
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2.9 Protein assay 
Protein assay was conducted according to the method ofLowry et al (1951). 
2.10 Statistical analysis 
Statistical analyses of the results were performed using one-way ANOVA, followed 
by Dunnett's test. A p value < 0.05 would be considered significance. Calculations of 
IC50 were performed by using Sigma Plot 9.0. 
2.11 Test compounds 
The following compounds were studied in the present investigation. The compounds 
were obtained from Sigma-Aldrich (USA) except chrysophanol from Fluka (Germany) 
and 6-gingerol from Wako (Japan). The chemicals were supplied in the purities as 
shown below with certificates of analysis issued by the suppliers and were directly 
used in the present study without further purification. 
• 6-Gingerol (>98%) 
• Aloe-emodin (>95%) 
•:• Barbaloin (>96%) 
•:• Chrysophanol (>98%) 
• Deoxyrhapontin (>99%) 
•:• Rhapontin (>99%) 
• Rhein (>85%) 
The chemical structures of these compounds are shown in Chapter 1. 
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Chapter 3 Xanthine oxidase inhibition assay: 
results and discussion 
3.1 Introduction 
Enzymes are functional protein molecules with catalytic activities. They convert 
target substrates into products in chemical reactions. Enzyme works by lowering the 
energy of the transition-state, the formation of products can then be achieved much 
faster than the non-catalyzed reactions. In order to lower the activation energy, 
enzyme forms complex with substrate which results in an enzyme-substrate-complex. 
The fitting mechanism between enzyme and substrate depends on the "lock-and-key" 
hypothesis or the "induced fit" hypothesis. After that, suitable chemical groups on the 
substrate interact with the functional groups in the active site of enzyme and enhance 
alteration of structural conformation of the enzyme. As an enzyme is specific to its 
own substrate, unsuitable molecule is unable to fit. When the product is formed，its 
structure no longer fits the orientation of the active site, and is being expelt from the 
active site. At the active site, the presence of cofactors, which is either a metal ion or 
an organic molecule, may assist the function of the enzyme. 
XOD is a key enzyme which participates in the purine degradation pathway. It has a 
molecular weight of 300,000. It is responsible for the conversion of xanthine into uric 
acid, with superoxide radicals produced at the same time. As a result, it plays a 
significant role in the pathophysiology of hyperuricemia and ischemia/reperfusion 
injury. XOD exists in two forms, the NAD十-dependent dehydrogenase form and the 
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oxygen-dependent oxidase form (Moriwaki et al., 1999). XOD can be converted from 
XDH under certain circumstances. They are located in the organs of many warm-
blooded animals such as liver, heart, lung, intestine, skeletal muscles, kidney, etc. 
(Moriwaki et al.’ 1999). 
The reaction of enzyme depends on the concentration of substrate. When substrate is 
in excess, reaction rate is directly proportional to the concentration of enzyme. The 
Michaelis-Menten equation of enzyme kinetics is as follow (Silverman, 2000): 
V = Y m a x� s ] 
Km+[S] 
where: 
V = rate of reaction 
Vmax = maximum rate of reaction 
[S] = concentration of substrate 
Km = Michaelis-Menten constant=dissociation constant of enzyme-substrate complex 
In order to find out the values of Vmax and Km, the Michaelis-Menten equation is 
converted to the double reciprocal form (Silverman, 2000): 
l / v = K m / V _ ( l / [ S ] ) + l / V 匪 
In the Lineweaver-Burk plot, 1 / v is plotted against 1 / [S], with slope = Km / Vmax, 
y-intercept = 1 / Vmax and x-intercept = -1 / Km. 
In competitive inhibition, the inhibitor competes with the substrate for the same active 
site of the enzyme such that the inhibitor prevents the substrate from binding to the 
active site of the enzyme. From the Michaelis-Menten equation, the equation for 
competitive inhibition is derived (Silverman, 2000): 
_ V 腿[SI 
v= Km(l + [ I ] /K i ) + [S] 
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where: 
[I] = concentration of inhibitor 
Ki = dissociation constant of enzyme-inhibitor complex 
Km = Michaelis-Menten constant=dissociation constant of enzyme-substrate complex 
In order to construct the Lineweaver-Burk plot for evaluating the mode of inhibition, 
this equation is converted into the double reciprocal (Silverman, 2000): 
l / v = Km/Vmax(l/[S])( l + [ I ] /K i )+ l /Vmax 
When 1 / V is plotted against 1 / [S] in the Lineweaver-Burk plot, slope = Km/ Vmax (1 
+ [I] / Ki), y-intercept = 1 / V^ax and x-intercept = -1 / Km (1 + [I] / Ki). The 
intersection of lines which varies in [I] should intersect on the y-axis. 
In non-competitive inhibition, the inhibitor binds to the free enzyme at a site away 
from the active site. It can also bind to the enzyme-substrate complex to form the 
enzyme-substrate-inhibitor complex. It is assumed that the dissociation of substrate 
from the enzyme-substrate complex is the same as from the enzyme-substrate-
inhibitor complex. From the Michaelis-Menten equation, the equation for non-
competitive inhibition is represented by (Silverman, 2000): 
v= V m j s m i + m/Ki:) 
(Km + [S]) 
where: 
[I] = concentration of inhibitor 
Ki = dissociation constant of enzyme-inhibitor complex 
Km = Michaelis-Menten constant=dissociation constant of enzyme-substrate complex 
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In order to construct the Lineweaver-Burk plot for evaluating the mode of inhibition, 
this equation is converted into the double reciprocal form (Silverman, 2000): 
1 / V = {Km/ Vmax (1 丨[S]) + 1 / Vmax} (1 + [I] / Kj) 
When 1 / V is plotted against 1 / [S] in the Lineweaver-Burk plot, slope = Km / Vmax (1 
+ [I] / Ki), y-intercept = 1 / Vmax (1 + [I] / Ki) and x-intercept = -1 / Km. The 
intersection of lines which varies in [I] should intersect on the x-axis. 
In uncompetitive inhibition, inhibitor binds to the enzyme-substrate complex to form 
the enzyme-substrate-inhibitor complex, but it cannot bind to the free enzyme. It is 
assumed that the dissociation of substrate from the enzyme-substrate complex is the 
same as from the enzyme-substrate-inhibitor complex. From the Michaelis-Menten 
equation, the equation for uncompetitive inhibition is represented by (Silverman, 
2000): 
v= v j s m i + nn/KM 
K n , / ( H - [ I ] / K ' i ) + [S] 
where: 
[I] = concentration of inhibitor 
K 'i = dissociation constant of enzyme-substrate-inhibitor complex 
Km = Michaelis-Menten constant=dissociation constant of enzyme-substrate complex 
In order to construct the Lineweaver-Burk plot for evaluating the mode of inhibition, 
this equation is converted into the double reciprocal form (Silverman, 2000): 
1 / V = Km/ Vmax (1 丨[S]) + 1 / V ^ x (1 + [I]丨 Ki) 
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When 1 / v is plotted against 1 / [S] in the Lineweaver-Burk plot, slope = Km/ Vmax，y-
intercept = 1 / Vmax (1 + [I]丨 K!) and x-intercept = -(1 + [I] / K{) / Km. The lines of 
varying [I] are parallel to each other without any intersection. 
In mixed inhibition, the inhibitor binds to the enzyme-substrate complex to form the 
enzyme-substrate-inhibitor complex, and it can also bind to the free enzyme. It 
possesses the characteristics of some non-competitive and some uncompetitive 
inhibition (Owen and Johns, 1999). In order to construct the Lineweaver-Burk plot for 
evaluating the mode of inhibition, the following equation is applied (Silverman, 2000): 
1 / V = K m / V臓 ( 1 / [S]) (1 + [I] / Ki) + 1 / Vmax (1 + [I]丨 K'i) 
where: 
[I] = concentration of inhibitor 
Ki = dissociation constant of enzyme-inhibitor complex 
K' i = dissociation constant of enzyme-substrate-inhibitor complex 
Km = Michaelis-Menten constant=dissociation constant of enzyme-substrate complex 
When 1 / V is plotted against 1 / [S] in the Lineweaver-Burk plot, slope = Km/ Vmax (1 
+ [I] / Ki), y-intercept = 1 / V^ax (1 + [I] / K'O and x-intercept = -(1 + [I] / K'O / Km (1 
+ [I] / Ki). The intersection of lines with varying [I] would not be exactly on the x-
axis (Silverman, 2000). Also, the values of Ki and K'i could be calculated accordingly. 
In the present study, it was found that one of the test compounds possessed mixed 
type inhibition, so the equation for mixed inhibition was applied. 
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The XOD assay was carried out in order to evaluate the inhibitory potency of the test 
compounds towards XOD. The assay was performed according to the protocols as 
described in the Materials and methods chapter. 
3.2 Results 
Among the test compounds, deoxyrhapontin elicited inhibitory activity towards XOD 
in a dose-dependent manner. From figure 3.1，it was found that its IC50 value was 
about 114.7 |j,M. The IC50 of the positive control, allopurinol, was found to be 8.2 |j.M, 
which was similar to the value reported previously (Li et al., 1999). Deoxyrhapontin 
was a reversible enzyme inhibitor, as shown in Figure 3.2. Moreover, the inhibitory 
mode of deoxyrhapontin is of the mixed type, as shown in Figure 3.3. On the other 
hand, other test compounds had no observable inhibitory effect at their maximum 
concentrations tested. The results are shown in Table 3.1. The Kj and K'i values of 
deoxyrhapontin were calculated to be 72.2|j,M and 345.3|j,M respectively. The mode 
of inhibition of some structurally related compounds on XOD are shown in Table 3.2. 
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Figure 3.1 Dose-dependent inhibitory actions of deoxyrhapontin (Panel A) and 
allopurinol (Panel B) on XOD. The assay was conducted with 0.089U/ml XOD and 
0.12mM xanthine. The extent of enzyme inhibition is expressed as percentage activity 
which is plotted against different concentrations of the inhibitor. Data were obtained 
from the average of three (for deoxyrhapontin) or four (for allopurinol) independent 
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Figure 3.2 Reversibility studies of the inhibitory effects of deoxyrhapontin (Panel A) 
and allopurinol (Panel B) on XOD. Change in absorbance at 295nm is compared 
among two groups: the control and sample without dilution after incubation, the 
control and sample with dilution after incubation. Both groups contained same 
concentrations of enzyme and substrate during measurement of absorbance. Data 
were obtained from the average of three (for deoxyrhapontin) or four (for allopurinol) 
independent experiments and the error bars indicate standard deviations. D = 
Deoxyrhapontin, A = Allopurinol. 
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Figure 3.3 Lineweaver-Burk plot of XOD inhibition by deoxyrhapontin. Enzyme 
activity was expressed as change in absorbance at 295nm per min. The reciprocal of 
absorbance change is plotted against the reciprocal of substrate concentration. The 
concentrations of substrate used were 6|j,M, 10|j,M, 15|_iM，20)j,M, 40|_iM, 60|j,M and 
120|j,M. Each experiment consists of three conditions: control without any inhibitor 
(•)，in the presence of 50j_iM deoxyrhapontin (•)，and in the presence of 70|j,M 
deoxyrhapontin ( • ) . The straight lines were generated by linear regression of the 
points. The values represent the average of duplicate experiments. 
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Table 3.1 The inhibitory effects of different compounds on XOD activity. 
Test compounds Maximum conc. tested Effect 
6-Gingerol 200 )liM Inactive 
Aloe-emodin 100 }j,M Inactive 
Barbaloin 200 |j,M Inactive 
Chrysophanol 100)jM Inactive 
Rhapontin 100 juM Inactive 
Rhein 100 |j,M Inactive 
The concentrations shown in the table are the maximum final concentrations of the 
compounds. 
Table 3.2 XOD inhibitory effects of several structurally similar compounds. 
Inhibitor IC50 (^M) Type of Kj ( i^M) K，i ( _ ~ 
inhibition 
Deoxyrhapontin 114.7 mixed 72.2 345.3 
Resveratrol 11.0 competitive 9.7 ---
Piceid 66.1 competitive 14.3 —-
Isorhapontin 70.0 competitive 19.1 ™ 
Comparison of the XOD inhibitory effects of deoxyrhapontin, resveratrol, piceid and 
isorhapontin (Zhou et al.’ 2001). 
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3.3 Discussion 
As XOD plays an important role in hyperuricemia, compounds with inhibitory 
activities on this enzyme would be able to alleviate the pathologic conditions in 
hyperuricemic patients. Deoxyrhapontin elicited inhibitory activity on XOD, but 
rhapontin (which is structurally similar) as well as other test compounds did not. The 
IC50 value of deoxyrhapontin is larger than allopurinol, meaning that deoxyrhapontin 
is less potent than allopurinol. Moreover, a Lineweaver-Burk plot was drawn on the 
deoxyrhapontin inhibition to evaluate the mode of inhibition. Deoxyrhapontin was 
found to be a mixed inhibitor, since the Lineweaver-Burk plots of its inhibition on 
XOD intersect on the left of the 1/v axis and above the 1/[S] axis (Figure 3.3). 
Therefore, deoxyrhapontin belongs to the mixed type inhibition in which K，i〉Ki. 
In the reversibility assay, the activity of XOD was restored after dilution in the 
presence of deoxyrhapontin. In the case of allopurinol, the enzyme activity was not 
restored. These results revealed that deoxyrhapontin is a reversible inhibitor, whereas 
allopurinol is not (Hotter et al,, 1994). In other words, the inhibitory effect of 
deoxyrhapontin can be eliminated when the inhibitor is removed, so the enzyme 
becomes active again. Nevertheless, the inhibitory effect of allopurinol remains upon 
dilution. 
Structure-activity relationship was compared among deoxyrhapontin, rhapontin and 
other structurally-related compounds, in order to understand their difference in effects. 
Resveratrol and isorhapontin are two of the stilbenoids isolated from Veratrum 
taliense (Liliaceae). They are competitive inhibitors of XOD and they possess similar 
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structures with deoxyrhapontin and rhapontin (Zhou et al., 2001). By comparing the 
potency of the compounds, it was found that the one with the highest inhibitory ability 
is resveratrol, followed by piceid, isorhapontin and deoxyrhapontin, whereas 
rhapontin has no effect at all. The IC50 values of resveratrol, piceid and isorhapontin 
have been reported to be llj j,M, 66.1jaM and 70^M respectively (Zhou et al., 2001), 
which is lower than the determined value for deoxyrhapontin, 114.7jj.M, in the present 
study. Moreover, allopurinol was used as the positive control in the study of Zhou et 
al., 2001 and the present study. The IC50 values of allopurinol obtained in both studies 
were similar. The structures of the compounds were inspected. The compounds differ 
in their inhibitory actions despite their high degree of structural similarity, possibly 
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Figure 3.4 Chemical structures of deoxyrhapontin, rhapontin and their analogs. 
For resveratrol, its hydroxyl groups are located at the para (p) position in benzene 
ring B and the meta (m) positions in benzene ring A. Delocalization of electrons 
between the lone pair electrons of the phenoxyl oxygen and tt electrons in the benzene 
ring occurs and the compound becomes electron-rich. This may enable the compound 
to interact with the molybdenum active center of the enzyme (Medvedev et al., 1995; 
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Stupans and Ryan, 1984). As resveratrol has the smallest IC50 value among the 
compounds (Table 3.2)，that means its structure may produce the strongest XOD 
inhibition. Although piceid possesses the same structure in benzene ring B as that in 
resveratrol, it has a glucosyl group instead of a hydroxyl group at one of the m 
position of benzene ring A. It is less potent than resveratrol. This shows that 
glycosylation may make the compound bulky and reduces its inhibitory ability 
(Chang et al.’ 1994; Chan et al” 1995; Zhou et al., 2001). 
For isorhapontin, there is an additional methoxyl group located at the m position of 
benzene ring B when compared to the structure of piceid. As its IC50 is larger than 
piceid, it implies that addition of methoxyl group may decrease the inhibition potency 
of the compound (Chang et al., 1994; Chan et al” 1995). For rhapontin, its only 
structural difference with isorhapontin is the exchange of position between the 
methoxyl group and the hydroxyl group on benzene ring B. The hydroxyl group 
located at the m position instead of the p position of ring B may decrease inhibitory 
effect. For deoxyrhapontin, it only has a methoxyl group on the p position of benzene 
ring B. It has a similar structure to rhapontin, the only difference is the absence of a 
hydroxyl group at the m position, but it has a higher inhibitory activity than rhapontin. 
Deoxyrhapontin and rhapontin possess lower inhibition potency than the other three 
compounds, showing that methylation of hydroxyl group at the p position may 
decrease inhibitory activity (Shin et al., 1998; Kim et al., 2002). 
As shown in the IC50 values of resveratrol and other stilbenes, the numbers and 
position of hydroxyl groups are essential for the XOD inhibitory activities of the 
stilbenes. Hydroxyl group possesses a higher electron-donating property than 
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methoxyl group or glucosyl group. Stronger electron delocalization is achieved in 
resveratrol than in piceid, as the stronger electron-donating hydroxyl group is present 
at the m position of benzene ring A instead of a glucosyl group. Moreover, the 
presence of the w-hydroxyl group on benzene ring B of rhapontin instead of the p-
hydroxyl group in isorhapontin may decrease its electron density, as delocalization of 
electrons between the lone pair electrons of oxygen and the tt electrons of the benzene 
ring is weaker comparatively. This may be due to the spatial arrangement of oxygen 
atom at the m position which is unable to exert maximum electron delocalization as it 
is in the p position. A higher electron density may be present in deoxyrhapontin as 
compared to rhapontin. The additional hydroxyl group at the m position of benzene 
ring B of rhapontin may decrease the potency as it does not contribute to the increase 
of electron density. It reduces the electron density instead due to counteraction with 
the hydroxyl group at the m position of benzene ring A. As a result, rhapontin has the 
least inhibitory effect. Furthermore, the anthraquinones did not exhibit XOD 
inhibitory effects in the present study, this agrees with the results of a similar study in 
the past (Sheu and Chiang, 1997). 
Further in vivo studies and clinical trials are required to evaluate the potential of 
deoxyrhapontin and other stilbenoids in treating hyperuricemia. 
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Chapter 4 Lipid peroxidation inhibition in mouse 
liver microsomes: results and discussion 
4.1 Introduction 
Lipid is an important component of cell membranes. Free radicals produced by either 
natural physiological reactions or unnatural chemical reactions such as radiation may 
cause lipid peroxidation of the membrane. This chapter aims at evaluating the 
effectiveness of the test compounds in the prevention of lipid peroxidation. The assay 
was performed according to the protocols described in the Materials and methods 
chapter. 
4.2 Results 
Figure 4.1 shows the results of trolox as the positive control. Its IC50 was determined 
to be 82.9|j,M. Among the test compounds, 6-gingerol and rhapontin possessed 
inhibitory effects towards lipid peroxidation in a dose-dependent manner. Figure 4.2 
shows the effect of 6-gingerol. Its IC50 was found to be 66.3|jM. Figure 4.3 shows the 
results of rhapontin. Its IC50 was determined to be 154.8|aM. Other test compounds 
did not exhibit any positive effects at their maximum final concentrations used (Table 
4.1). The relative potencies of the test compounds with positive effects in comparison 
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Figure 4.1 The inhibitory effect of trolox on mouse liver microsomal lipid 
peroxidation. In the assay, O.OlmM FeS04 and O.lmM ascorbic acid were applied in 
the absence (control) or presence of various concentrations of trolox. Results are 





80 - \ 
70 - \ 
1 6。_ \ 
2 50- \ 




0 J , , , ^ , 
0 50 100 150 200 250 
[6-Gingerol] (|aM) 
Figure 4.2 The inhibitory effect of 6-gingerol on mouse liver microsomal lipid 
peroxidation. In the assay, O.OlmM FeSCU and O.lmM ascorbic acid were applied in 
the absence (control) or presence of various concentrations of 6-gingerol. Results are 
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Figure 4.3 The inhibitory effect of rhapontin on mouse liver microsomal lipid 
peroxidation. In the assay, O.OlmM FeSCU and 0.1 mM ascorbic acid were applied in 
the absence (control) or presence of various concentrations of rhapontin. Results are 
expressed as percentage of control. Data represent mean 士 S.D. of four independent 
experiments. 
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Table 4.1 The inhibitory effects of different compounds on mouse liver microsomal 
lipid peroxidation. 
Test compounds Maximum conc. tested Effect 
Aloe-emodin 100 Inactive 
Barbaloin 100 Inactive 
Chrysophanol 100 Inactive 
Deoxyrhapontin 100 Inactive 
Rhein 100 [xM Inactive 
The concentrations shown on the table are the maximum final concentration of 
compounds tested according to the protocol described in the Materials and methods 
chapter. 
Table 4.2 The relative potencies of test compounds on the inhibition of mouse liver 
microsomal lipid peroxidation. 
Test compounds IC50 Relative potency 
Trolox 82.9 |liM 1 
6-Gingerol 66.3 ^iM ^ 
Rhapontin 154.8 |_iM 
Their IC50 values are compared against trolox, which is the positive control Relative 
potency = IC50 of trolox / IC50 of test compound. 
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4.3 Discussion 
After examining the XOD inhibitory effects on the test compounds, we proceeded to 
study the compounds' ability to protect against lipid peroxidation. Mouse liver 
microsome acts as a lipid source in the assay. This assay investigates the ability of the 
compounds to protect the cell membrane from being oxidized. In the presence of Fe^^ 
which is a transition metal ion, ascorbic acid acts as a pro-oxidant (Higuchi et al.’ 
2003) and hydroxyl radicals would be formed in the presence of oxygen. This induces 
free radical-mediated lipid peroxidation of a liver microsomal preparation. As a result, 
lipid peroxides are produced due to free radical propagation (Messina et al., 1991). 
MDA is produced as the final product of lipid peroxidation. MDA could be detected 
after reacting with TBA. The absorbance of the pink color adduct could be monitored 
colorimetrically at 532nm. 
Among the test compounds, 6-gingerol and rhapontin exhibited inhibitory actions on 
lipid peroxidation of liver microsomes in a dose-dependent manner. Comparing the 
IC50 values of 6-gingerol and rhapontin to that of trolox, it is found that 6-gingerol is 
slightly more potent than trolox in inhibiting the formation of MDA whereas 
rhapontin appeared to be one-half as potent as trolox (Table 4.2). In other reports, 6-
gingerol has been found to be four times more potent than a-tocopherol by using the 
ferric thiocyanate method for incubation (Kikuzaki et al., 1993) and two times less 
potent than propyl gallate by using ox brain phospholipid liposomes as the lipid 
source (Aeschbach et al” 1994). This assay confirms the antioxidant effect of 6-
gingerol by using mouse liver microsomes as the lipid source which has never been 
applied before. 
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The antioxidative activities of 6-gingerol and rhapontin in lipid peroxidation might be 
related to the number and steric position of the functional groups on the compounds 
(Cao et al., 2003). Rhapontin has a higher IC50 value than 6-gingerol. The presence of 
a bulky glucoside moiety may hinder its antioxidative activity (Matsuda et al； 2000). 
Although 6-gingerol and rhapontin possess the same number of hydroxyl and 
methoxyl group at the benzene ring, the position of the constituent groups are 
exchanged. 6-Gingerol has a stronger effect as its hydroxyl group is located at the p 
position, enabling it to form a phenoxyl radical more readily due to a stronger 
resonance within the structure (Nakao et al.’ 1998). Furthermore, the difference in the 
antioxidative effect of rhapontin and deoxyrhapontin may be due to the absence of a 
phenol group in benzene ring B for deoxyrhapontin. This renders it impossible to 
form a phenoxyl radical (Matsuda et al., 2000). Rhapontin was able to form a stable 
phenoxyl radical, which might stop peroxide propagation reactions in lipids (Nakao et 
al., 1998). 
After screening the test compounds with lipid peroxidation inhibition assay of mouse 
liver microsomes, assays of RBC and LDL were performed to evaluate the 
antioxidative effect of the compounds in detail. 
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Chapter 5 Assays on protection of RBC from 
oxidative damage: results and discussion 
5.1 Introduction 
RBC constitute an important blood component as they contain hemoglobin and carry 
oxygen. Their life span lasts for about 120 days (Surgenor, 1974). Any abnormal 
hemolysis may cause serious diseases. No matter hemolysis is caused by congenital or 
noncongenital defects, protection of RBC from lysis would benefit the patients. 
AAPH has been employed as a common free radical inducer in many oxidative stress 
systems. It is also applied for AAPH-induced hemolysis inhibition assay and LDL 
lipid peroxidation inhibition assay in the present investigation. 
NH 
C—NH2 Me NH 
M e — C — N = N — C — C — N H 2 
Me Me 
• 2 HCl 
Chemical structure of AAPH. 
The formation of AAPH peroxyl radical was responsible for inducing oxidative 
damage in biological systems. The AAPH-induced hemolysis inhibition assay is 
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performed to evaluate the protective abilities of the test compounds towards RBC 
lysis. In the assay, carbon-centered radicals (R.) derived from AAPH (R—N=N—R) 
attack RBC to induce hemolysis (Ou et al” 2002). 
R—N=N—R > 2R' + N2 
AAPH could produce peroxyl radicals (ROO*) to induce the formation of lipid 
radicals (L* and LOO*) which are the lipid peroxidation intermediates on cell 
membranes. Lipid peroxides (LOOH) are formed from lipids (LH) (Ou et al., 2002). 
R' + 02 >R00' 
ROO. + LH > ROOH + L' 
L. + 02 >L00* 
LOO. + LH > LOOH + V 
Apart from assessing the compounds' protective ability towards AAPH-induced 
hemolysis, it is essential to observe whether the test compounds prevent the major 
membrane component, lipid, from undergoing oxidation reaction. RBC do not have 
nucleus, mitochondria and other cellular organelles. Therefore, their membranes can 
be prepared without contamination by other intracellular organelles (Alberts et al., 
1994). The lipid peroxidation inhibition assay of RBC membrane was designed to 
investigate the degree of lipid peroxidation in RBC membrane by the amount of lipid 
peroxidation product, MDA, produced. Hemin initiates lipid peroxidation when 
organic peroxides such as /BHP are present. 
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ATPase is another target apart from the membrane lipids. ATPase is a carrier protein 
that transports substances across the plasma membrane by reversible conformational 
change (Alberts et al” 1994). Ion transport is done by exposing the binding site on 
both sides of the membrane alternatively. ATPase controls ion permeability across the 
membrane at the expense of energy. It plays an important role in cellular structure and 
function. By controlling cell volume and osmotic balance, ATPase is responsible for 
maintaining cell integrity (Alberts et al” 1994). ATPase assay is applied to investigate 
whether the test compounds can protect ATPase from inactivation by ROS. The RBC 
ATPase is thus a good diagnostic indicator as blood can be obtained easily and 
ATPase assay can be easily performed. The ATPase assay was therefore used to 
evaluate the test compounds' protective abilities in maintaining the RBC ATPase 
activities. 
Ca2+-ATPase and Na+/K+-ATPase are found on RBC membrane. Ca^ "" ion is 
transported by Ca2+-ATPase for cell signaling and Na+ and K+ ions are transported by 
Na+/K+-ATPase to maintain cellular osmolality and many other cellular functions. I f 
the test compounds could protect these ATPases, they might contribute to the 
protection of cell membrane integrity. Ca〗.-ATPase pumps Ca^ ^ ions out of the cell 
against a steep concentration gradient. This active transport requires energy. This 
explains the influx of Ca^^  ions and the demand of active transport for homeostasis. 
Alteration of intracellular level of Ca^^  ions affects cell signaling. 
Na+/K+-ATPase is made up of a large transmembrane catalytic subunit in association 
with a small glycoprotein (Alberts et al., 1994). Na+/K+-ATPase pumps three Na+ ions 
out of the cell and two K+ ions into the cell for each ATP molecule hydrolyzed, 
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keeping the cell membrane negatively charged inside and positively charged outside 
(Alberts et al., 1994). This active transport is against the steep concentration gradients 
of the two ions. This explains the entrance of Na+ ion and the demand of active 
transport for homeostasis. The resulting Na+ ion concentration gradient regulate 
cellular osmotic balance and facilitates the uptake of useful substances including 
glucose into the cell. 
In order to further understand the protective mechanism of the test compounds on 
RBC, sulfhydryl group protection assay was also performed. As sulfhydryl groups 
present in proteins are prone to ROS attack, this assay would enable us to observe 
whether the test compounds could help preserve the protein structure of RBC 
membrane. In addition, the reduced state of some of the sulfhydryl groups in ATPase 
is important for their activities. The present study would also enable us to understand 
whether preservation of ATPase activities by the compounds are related to their 
sulfhydryl group-protecting effects. All the above assays were performed according to 
the protocols described in the Materials and methods chapter. 
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5.2 Results 
5.2.1 AAPH-induced hemolysis inhibition assay 
Figure 5.1 shows the effect of different concentrations of AAPH on AAPH-induced 
hemolysis. From the results, the optimal condition for the assay was determined. 
Figure 5.2 shows the putative effect of vitamin C. Its IC50 was determined to be 
120.3jaM. Figure 5.3 shows the protective effect of trolox. Its IC50 was found to be 
59.2p.M. Figures 5.4，5.5 and 5.6 show the results of 6-gingerol, barbaloin and 
rhapontin respectively. The IC50 of 6-gingerol was determined to be 95.3|aM, 
barbaloin 31.7jj,M, and rhapontin 31.9|aM. Other test compounds did not exhibit any 
statistically significant protective effects towards RBC at their highest concentrations 
tested. The results are shown in Table 5.1. The relative potencies of the test 
compounds are shown in Table 5.2. 
7 5 
100 n 
90 - • . 
80 - • 7�- I 
圣 60 - • 
i 5。- • • I I 
^ 30 - • • • i l l I 
0 12.5 25 50 75 100 
[AAPH] (mM) 
Figure 5.1 The dose-dependent AAPH-induced hemolysis. This is a preliminary 
experiment for obtaining the appropriate concentration of AAPH to be applied in 
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Figure 5.2 The inhibitory effect of vitamin C on AAPH-induced hemolysis. The 
assay was conducted with lOOmM AAPH, in the absence (control) or presence of 
various concentrations of vitamin C. Results are expressed as the percentage of RBC 
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Figure 5.3 The inhibitory effect of trolox on AAPH-induced hemolysis. The assay 
was conducted with lOOmM AAPH, in the absence (control) or presence of various 
concentrations of trolox. Results are expressed as the percentage of RBC lysed. Data 
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Figure 5.4 The inhibitory effect of 6-gingerol on AAPH-induced hemolysis. The 
assay was conducted with lOOmM AAPH, in the absence (control) or presence of 
various concentrations of 6-gingerol. Results are expressed as the percentage of RBC 
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Figure 5.5 The inhibitory effect of barbaloin on AAPH-induced hemolysis. The 
assay was conducted with lOOmM AAPH, in the absence (control) or presence of 
various concentrations of barbaloin. Results are expressed as the percentage of RBC 
lysed. Data represent mean 士 S.D. of four independent experiments. 
8 0 
100 ^ 
90 T i > 
80 -i 
I 7。 - i 
^ 60 - \ 
O I 
CQ 50 - ‘ 
、 4 。 人 
^ 30 -
20 - ^ ^ ^ ^ ^ ^ ^ ^ 
10 - ^ ^ 
0 ‘ ‘ ‘ ‘ 
0 100 200 300 400 
[Rhapontin] (joM) 
Figure 5.6 The inhibitory effect of rhapontin on AAPH-induced hemolysis. The 
assay was conducted with lOOmM AAPH, in the absence (control) or presence of 
various concentrations of rhapontin. Results are expressed as the percentage of RBC 
lysed. Data represent mean 士 S.D. of four independent experiments. 
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5.2.2 Lipid peroxidation inhibition assay of RBC membranes 
Figure 5.7 shows the effect of hemin on RBC membrane lipid peroxidation. From the 
results, the optimal assay condition was determined. Figure 5.8 demonstrates the 
protective effect of trolox. Its IC50 was determined to be 224.4|iM. Figure 5.9 shows 
the protective effect of 6-gingerol. Its IC50 was found to be 20.7|^M. Figure 5.10 
shows the protective effect of barbaloin. Its IC50 was determined to be Tl.OfiM. 
Figure 5.11 shows the protective effect of rhapontin. Its IC50 was found to be 38.3|j,M. 
These three compounds protect lipid from oxidization in a dose-dependent manner. 
Table 5.3 shows the results of other test compounds. They did not exhibit any 
inhibitory effects on lipid peroxidation at the concentrations tested in the presence of 
hemin. The relative potencies of the test compounds are shown in Table 5.4. 
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Figure 5.7 The effect of hemin on RBC membrane lipid peroxidation. This is a 
preliminary experiment for obtaining the appropriate concentration of hemin to be 
applied in subsequent assays. Various concentrations of hemin were applied in the 
presence of 0.5mM /BHP with 4 h of incubation. Results are expressed as the 
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Figure 5.8 The inhibitory effect of trolox on lipid peroxidation of RBC membrane. 
The assay was conducted with 0.5mM rBHP and hemin, in the absence 
(control) or presence of various concentrations of trolox. Results are expressed as the 
percentage of control. Data represent mean 士 S.D. in three independent experiments. 
The results were compared to the control with oxidative damage by one-way ANOVA 
followed by Dunnett's test. *,p < 0.05; ***’；？< 0.001. 
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Figure 5.9 The inhibitory effect of 6-gingerol on lipid peroxidation of RBC 
membrane. The assay was conducted with 0.5mM tBHP and 1.5|iM hemin, in the 
absence (control) or presence of various concentrations of 6-gingerol. Results are 
expressed as the percentage of control. Data represent mean 士 S.D. in four 
independent experiments. The results were compared to the control with oxidative 
damage by one-way ANOVA followed by Dunnett's test. * , p < 0.05; ***,/?< 0.001. 
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Figure 5.10 The inhibitory effect of barbaloin on lipid peroxidation of RBC 
membrane. The assay was conducted with O.SmM rBHP and 1.5|aM hemin, in the 
absence (control) or presence of various concentrations of barbaloin. Results are 
expressed as the percentage of control. Data represent mean 士 S.D. in four 
independent experiments. The results were compared to the control with oxidative 
damage by one-way ANOVA followed by Dunnett's test. ***,/? < 0.001. 
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Figure 5.11 The inhibitory effect of rhapontin on lipid peroxidation of RBC 
membrane. The assay was conducted with 0.5mM ？BHP and l.SjaM hemin, in the 
absence (control) or presence of various concentrations of rhapontin. Results are 
expressed as the percentage of control. Data represent mean 士 S.D. in four 
independent experiments. The results were compared to the control with oxidative 
damage by one-way ANOVA followed by Dunnett's test. ***，；？ < 0.001. 
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5.2.3 Ca^^-ATPase protection assay 
Figure 5.12 is the standard curve for Pi. Figures 5.13, 5.14, and 5.15 show the effect 
of Triton X-100，hemin and fBHP respectively on Ca^ '^-ATPase activity of RBC 
membrane. From these results, the optimal assay conditions were determined. Figure 
5.16 shows the protective effect of the positive control, trolox. A concentration of 
ImM was chosen for the subsequent assays as this gave the maximum degree of 
protection. Figure 5.17 shows that barbaloin exhibited protection towards Ca^ -^
ATPase activity in a dose-dependent manner. Activity recovery at ImM was 42.30%. 
Activity recovery at ImM of trolox was found to be 46.47% in the same experiment. 
Other test compounds did not exhibit any protective effects on Ca -ATPase at the 
concentrations tested in the present /BHP/hemin prooxidation system. The results are 
shown in Table 5.5. The relative potencies of the test compounds are shown in Table 
5.6. The percentage of recovery instead of IC50 was used to calculate the relative 
potencies since activity recoveries for trolox and the test compounds with positive 
results could hardly reach 50%. 
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Figure 5.12 Standard curve for inorganic phosphate (Pi) determination. Different 
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Figure 5.13 The effect of Triton X-100 on Ca^"'-ATPase activity of RBC membrane. 
This is a preliminary experiment for obtaining the appropriate concentration of 
TritonX-100 to be applied in subsequent assays. Triton X-100 was applied in the 
resuspension buffer of the assay. Results are expressed as ATPase activity unit in 
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Figure 5.14 The effect of hemin on Ca2+-ATPase activity of RBC membrane. This is 
a preliminary experiment for obtaining the appropriate concentration of hemin to be 
applied in subsequent assays. Various concentrations of hemin were applied in the 
absence or presence of O.SmM rBHP. Results are expressed as ATPase activity unit in 
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Figure 5.15 The effect of rBHP on Ca '^^ -ATPase activity of RBC membrane. This is 
a preliminary experiment for obtaining the appropriate concentration of tBW to be 
applied in subsequent assays. The assay was conducted with l^iM and 2|_iM hemin, in 
the absence or presence of various concentrations of rBHP. Results are expressed as 
ATPase activity unit in nmol Pi/mg/min in one experiment. 
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Figure 5.16 The protective effect of trolox on Ca "^^ -ATPase activity against oxidative 
damage on RBC membrane. This is a preliminary experiment for obtaining the 
appropriate concentration of trolox to be applied in subsequent assays. The assay was 
conducted with O.SmM rBHP and 2|^M hemin, in the absence (control) or presence of 
various concentrations of trolox. Results are expressed as ATPase activity unit in 
nmol Pi/mg/min in one experiment. C = control without test compound. 
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Figure 5.17 The protective effect of barbaloin on Ca^^-ATPase activity against 
oxidative damage in RBC membrane. The assay was conducted with 0.5mM /BHP 
and 2|j,M hemin, in the absence (control) or presence of various concentrations of 
barbaloin. Results are expressed as ATPase activity unit in ninol Pi/mg/min. Data 
represent mean 土 S.D. in four independent experiments. C = control without test 
compound, T = ImM trolox. The results were compared to the negative control with 
oxidative damage by one-way ANOVA followed by Dunnett's test. *,/? < 0.05. 
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5.2.4 Na^/K^-ATPase protection assay 
Figures 5.18 and 5.19 show the effect of Triton X-100 and hemin respectively on 
Na+/K+-ATPase activity of RBC membrane. From these results, the optimal assay 
conditions were determined. Figure 5.20 shows the protective effect of the positive 
control, trolox. A concentration of ImM was chosen for the subsequent assays as this 
gave the maximum degree of protection. Figure 5.21 demonstrates that rhapontin 
exhibited protection on Na+/K+-ATPase in a dose-dependent manner. Activity 
recovery at ImM was 35.37%. Activity recovery at ImM of trolox was found to be 
55.09% in the same experiment. Table 5.7 shows the results of other test compounds. 
They did not exhibit any protective effects on Na+/K+-ATPase at the concentrations 
tested in the present rBHP/hemin prooxidation system. The relative potencies of the 
test compounds are shown in Table 5.8. The percentage of recovery instead of IC50 
was used to calculate the relative potencies since activity recoveries for trolox and the 
test compound with positive effects could hardly reach 50%. 
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Figure 5.18 The effect of Triton X-100 on Na+/K+-ATPase activity of RBC 
membrane. This is a preliminary experiment for obtaining the appropriate 
concentration of Triton X-100 to be applied in subsequent assays. Triton X-100 was 
applied in the resuspension buffer of the assay. Results are expressed as ATPase 
activity unit in nmol Pj/mg/min in one experiment. 
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0.5mM /BHP Figure 5.19 The effect of hemin on Na+/K+-ATPase activity of RBC membrane. This 
is a preliminary experiment for obtaining the appropriate concentration of hemin to be 
applied in subsequent assays. Various concentrations of hemin were applied in the 
absence or presence of 0.5mM ^BHP. Results are expressed as ATPase activity unit in 
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Figure 5.20 The protective effect of trolox on Na+/K+-ATPase activity against 
oxidative damage in RBC membrane. This is a preliminary experiment for obtaining 
the appropriate concentration of trolox to be applied in subsequent assays. The assay 
was conducted with 0.5mM rBHP and LS^iM hemin, in the absence (control) or 
presence of various concentrations of trolox. Results are expressed as ATPase activity 
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Figure 5.21 The protective effect of rhapontin on Na+/K+-ATPase activity against 
oxidative damage in RBC membrane. The assay was conducted with O.SmM /BHP 
and 1.5|J,M hemin, in the absence (control) or presence of various concentrations of 
rhapontin. Results are expressed as ATPase activity unit in nmol Pi/mg/min. Data 
represent mean ± S.D. in four independent experiments. C = control without test 
compound, T = ImM trolox. The results were compared to the negative control with 
oxidative damage by one-way ANOVA followed by Dunnett's test. * , p < 0.05; ***, 
p <0.001. 
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5.2.5 Sulfhydryl group protection assay 
Figure 5.22 shows the GSH standard curve. Figure 5.23 shows the loss of RBC 
membrane sulfhydryl groups in the presence of fBHP and varying amounts of hemin. 
From the results, the optimal assay conditions were determined. Figure 5.24 
demonstrates the protective effect of the positive control, trolox. A concentration of 
ImM was chosen as this gave the maximum degree of protection. Figure 5.25 shows 
that barbaloin exhibited protection towards sulfhydryl group in a dose-dependent 
manner. Its activity recovery at ImM was found to be 86.13%. Activity recovery at 
ImM of trolox was found to be 52.10% in the same experiment. Table 5.9 shows the 
results for other test compounds. They did not exhibit any protective effects on 
sulfhydryl groups at the concentrations tested in the present ^BHP/hemin prooxidation 
system. The relative potencies of the test compounds are shown in Table 5.10. 
Percentage of recovery instead of IC50 was used to calculate the relative potency. 
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Figure 5.22 Standard curve for GSH. Different concentrations of GSH vary with 
absorbance at 412nm in the assay. OD = optical density. 
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Figure 5.23 The loss of RBC membrane sulfhydryl groups in the presence of /BHP 
and varying amounts of hemin. This is a preliminary experiment for obtaining the 
appropriate concentration of ?BHP to be applied in subsequent assays. Various 
concentrations of hemin were applied in the absence or presence of 0.5mM ?BHP. 
Results are expressed as nmol SH/mg protein in one experiment. SH = sulfhydryl 
group, T = ImM trolox (with 0.5mM 出HP). 
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Figure 5.24 The protective effect of trolox on sulfhydryl groups against oxidative 
damage on RBC membrane. This is a preliminary experiment for obtaining the 
appropriate concentration of trolox to be applied in subsequent assays. The assay was 
conducted with 0.5mM rBHP and lOpM hemin, in the absence (control) or presence 
of various concentrations of trolox. Results are expressed as nmol SH/mg protein in 
one experiment. C= control without test compound, SH = sulfhydryl group. 
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Figure 5.25 The protective effect of barbaloin on sulfhydryl groups against oxidative 
damage on RBC membrane. The assay was conducted with 0.5mM /BHP and lOjiM 
hemin, in the absence (control) or presence of various concentrations of barbaloin. 
Results are expressed as nmol SH/mg protein. Data represent mean 土 S.D. in four 
independent experiments. C= control without test compound, T = ImM trolox, SH = 
sulfhydryl group. The results were compared to the negative control with oxidative 
damage by one-way ANOVA followed by Dunnett's test. *,p < 0.05; < 0.001. 
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Table 5.1 The inhibitory effects of different compounds on AAPH-induced 
hemolysis. 
Test compounds Maximum conc. tested Effect 
Aloe-emodin 50 ^iM Inactive 
Chrysophanol 50 {•iM Inactive 
Deoxyrhapontin 500 Inactive 
Rhein 1000 Inactive 
The concentrations shown in the table are the maximum final concentrations of the 
compounds. For l,8-Dihydroxy-3-methyl-anthraquinone and aloe-emodine, the 
concentrations shown are their maximum solubility in the assay. 
Table 5.2 The relative potencies of test compounds on the inhibition of AAPH-
induced hemolysis. 
Test compounds IC50 Relative potency 
Trolox 59.2 1 
6-Gingerol 95.3 ^iM 
Barbaloin 31.7 ^iM 
Rhapontin 31.9 j^M 
Vitamin C 120.3 |LtM 1 — 
6-Gingerol 95.3 |LIM 
Barbaloin 31.7 [iM 3J9 
Rhapontin 3 1 . 9 |LIM 
Their IC50 values are compared against trolox and vitamin C which were used as the 
positive controls. Relative potency = IC50 of trolox / IC50 of test compound or IC50 of 
vitamin C / IC50 of test compound. 
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Table 5.3 The inhibitory effects of different compounds on lipid peroxidation of 
RBC membrane. 
Test compounds Maximum conc. tested Effect 
Aloe-emodin 50 ^iM Inactive 
Chrysophanol 50 inM Inactive 
Deoxyrhapontin 500 ^iM Inactive 
Rhein 1000 jgM Inactive 
The concentrations shown in the table are the maximum final concentrations of the 
compounds. For l,8-Dihydroxy-3-methyl-anthraquinone, aloe-emodine, 
deoxyrhapontin and rhein, the concentrations shown are their maximum solubility in 
the assay. 
Table 5.4 The relative potencies of test compounds on the inhibition of RBC 
membrane lipid peroxidation. 
Test compounds IC50 Relative potency 
Trolox 224.4 1 
6-Gingerol 20.7 ^iM 10.84 
Barbaloin 71.0 |aM ^ ^ 
Rhapontin 38.3 |aM 
Their IC50 values are compared against trolox which was used as the positive control. 
Relative potency = IC50 of trolox / IC50 of test compound. 
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Table 5.5 The protective effects of different compounds on Ca^ -^ATPase activity of 
RBC membrane. 
Test compounds Maximum conc. tested Effect 
6-Gingerol 1000 Inactive 
Aloe-emodin 50 Inactive 
Chrysophanol 50 |iM Inactive 
Deoxyrhapontin 500 Inactive 
Rhapontin 1000 [ M Inactive 
Rhein 1000 ^iM Inactive 
The concentrations shown in the table are the maximum final concentrations of the 
compounds. 
Table 5.6 The relative potency of babaloin on the protection of Ca^ -^ATPase activity. 
Test compounds % Recovery Relative potency 
Trolox 46.47% 1 
Barbaloin 42.30% 0.91 
The percentages of ATPase activity recovered by ImM trolox and ImM barbaloin 
were compared. Relative potency = % recovery by test compound / % recovery by 
trolox. 
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Table 5.7 The protective effects of different compounds on Na+/K+-ATPase activity 
of RBC membrane. 
Test compounds Maximum conc. tested Effect 
6-Gingerol 1000 [liM Inactive 
Aloe-emodin 50 j^M Inactive 
Barbaloin 1000 yM Inactive 
Chrysophanol 50 [xM Inactive 
Deoxyrhapontin 500 |aM Inactive 
Rhein IQQQ ^ M Inactive 
The concentrations shown in the table are the maximum final concentrations of the 
compounds. 
Table 5.8 The relative potency of rhapontin on the protection of Na+/K+-ATPase. 
Test compounds % Recovery Relative potency 
Trolox 55.09% 1 
Rhapontin 35.37% 0.64 
The percentages of ATPase activity recovered by ImM trolox and ImM rhapontin 
were compared. Relative potency = % recovery by test compound / % recovery by 
trolox. 
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Table 5.9 The protective effects of different compounds on the sulfhydryl groups of 
RBC membrane. 
Test compounds Maximum conc. tested Effect 
6-Gingerol lOQQ }aM Inactive 
Aloe-emodin 50 [iM Inactive 
Chrysophanol 50 piM Inactive 
Deoxyrhapontin 500 yM Inactive 
Rhapontin 1000 t^M Inactive 
Rhein lOOQ Inactive 
The concentrations shown in the table are the maximum final concentrations of the 
compounds. 
Table 5.10 The relative potency of barbaloin on the protection of sulfhydryl groups 
of RBC membrane. 
Test compounds % Recovery Relative potency 
Trolox 52.10% 1 
“ Barbaloin 86.13% 1.65 
The percentages of sulfhydryl groups recovered by ImM trolox and ImM barbaloin 
were compared. Relative potency = % recovery by test compound / % recovery by 
trolox. 
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t I 5.3 Discussion 
5.3.1 AAPH-induced hemolysis inhibition assay 
( 
The inhibition of AAPH-induced hemolysis assay addresses a more physiological 
parameter for studying the mechanisms of free radical-derived diseases in vitro. The 
compounds are tested for their abilities to protect RBC from lysis. From the results, 6-
gingerol, barbaloin and rhapontin possess such protective abilities. The IC50 in 
ascending order is barbaloin, rhapontin and 6-gingerol. Barbaloin has the smallest 
IC50 value, meaning that it has the strongest antioxidant effect among them. The 
results were compared against the positive controls vitamin C and trolox, the common 
natural antioxidants. 6-Gingerol, barbaloin and rhapontin possess IC50 values smaller 
than vitamin C. In other words, they all exhibit higher protective abilities on RBC 
than vitamin C. Barbaloin and rhapontin possess smaller IC50 values than trolox, 
whereas 6-gingerol has a larger one. This means barbaloin and rhapontin are more 
potent than trolox and 6-gingerol in this case. 
Among the compounds with positive effects in this assay, barbaloin has the lowest 
IC50 value, followed by rhapontin, then 6-gingerol. The other compounds were 
inactive in this assay. This might be due to their poor solubility except 
deoxyrhapontin. The absence of hydroxyl group renders the formation of phenoxyl 
radical impossible in deoxyrhapontin (Nakao et al., 1998). 
Therefore, compounds with positive results were able to protect RBC from lysis due 
to either one or both of the following aspects. They include the ability to scavenge 
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AAPH-derived radicals to inhibit their attack on RBC membranes and the ability to 
terminate the propagation of chain reactions after the commencement of lipid 
peroxidation which might lead to the disintegration of RBC membranes. In fact, 
cellular membrane damage could be caused by peroxidation of membrane lipids, 
cross-linkage of membrane proteins or influx of ions. Upon the completion of RBC 
hemolysis assay, it is necessary to examine whether lipid peroxidation is the main 
reason for hemolysis on the exposure of RBC to oxidative stress. Therefore, the lipid 
peroxidation assay for RBC membrane was subsequently performed. 
5.3.2 Lipid peroxidation inhibition assay of RBC membranes 
After the hemolysis assay, it is necessary to observe the ability of the test compounds 
to inhibit RBC membrane lipid from oxidization. Lipid peroxidation consists of the 
lag phase, the propagation phase and the degradation phase. In this assay, the 
/BHP/hemin system was employed to initiate free radical production. Lipid peroxides 
and lipid peroxyl radicals were then formed (Marks et al； 1996). The chain reaction 
propagates unless it is stopped by an antioxidant. This in vitro reaction may represent 
certain pathophysiological conditions, as hemin was released into human blood during 
hemoglobin degradation. Excess hemin might cause oxidation to blood components 
due to the metal ion it possesses. 
MDA is produced as the product of lipid degradation and it forms complex with TBA. 
Fluorescence intensity of the adduct could thus reflect the amount of MDA. Results in 
this assay could explain whether the protective mechanisms of the test compounds 
involved lipid peroxidation inhibition. If the test compounds could exhibit positive 
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results in the lipid peroxidation inhibition assay of RBC membranes, it might protect 
RBC from lysis by inhibiting membrane lipid peroxidation. Regarding the results of 
hemolysis assay and RBC membrane lipid peroxidation assay, the test compounds 
which exhibited positive effects in the hemolysis assay also exhibited positive results 
in the RBC membrane lipid peroxidation assay. The results show that 6-gingerol, 
barbaloin and rhapontin protected RBC from lysis through inhibition of lipid 
peroxidation. The antioxidative effect of barbaloin, rhapontin and 6-gingerol, might 
probably be due to their abilities to form stable phenoxyl radicals (ArO*) (Ar = 
aromatic), enabling them to react with the AAPH-derived radicals or lipid peroxyl 
radicals, thus terminating the chain reaction (Ou et al” 2002). 
ArOH + R〇0. > ArO* + ROOH 
ArO. + R. > ArOR 
Comparing their IC50 values, 6-gingerol has the smallest, followed by rhapontin then 
barbaloin. They possess stronger antioxidative abilities than trolox. 6-Gingerol and 
rhapontin are able to scavenge free radicals. The phenol groups in their structures can 
form stable phenoxyl radicals by delocalization of electrons (Cao et al., 2003). 
OH 0" 0 
• 
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The phenoxyl radicals terminate chain propagation by reacting with the lipid radicals. 
6-Gingerol has the smallest IC50 value since it does not have a glycoside moiety to 
reduce its potency as in the case of rhapontin and barbaloin (Matsuda et al., 2000). 
Rhapontin has a larger IC50 value than 6-gingerol. The phenolic hydroxyl group of 
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rhapontin is located at the m position (Nakao et al” 1998). The resonance effect in this 
case is comparatively weaker than in a situation when the hydroxyl group is at the p 
position. Thus, phenoxyl radical may form less readily in rhapontin compared with 6-
gingerol. Although the phenol groups in the anthraquinone structure of barbaloin may 
be more difficult to become phenoxyl radicals due to the formation of intramolecular 
hydrogen bonds with the carbonyl oxygen, phenoxyl radical may form since the 
glucosyl group provides an attacking point for ROS. Other test compounds show 
negative results. It may be due to their poor solubilities. In order to understand 
whether the test compounds protect other membrane components apart from 
membrane lipid, the ATPase protection assays on RBC were subsequently performed. 
5.3.3 Ca^^-ATPase protection assay 
After performing the RBC membrane lipid peroxidation assay, compounds were 
assessed for their protective abilities towards ATPases, which are RBC membrane 
components. /BHP and hemin could generate free radicals that cross-link proteins thus 
inactivating RBC membrane Ca "^^ -ATPases. I f the test compounds possess positive 
effects in this assay, the Ca^^-ATPase activity would be spared after incubation with 
/BHP and hemin. In Ca -ATPase assay, barbaloin was found to protect Ca -ATPase 
activity against the action of /BHP and hemin. Its percentage of recovery was 
compared against trolox. It has a weaker potency than trolox at the same 
concentration. 
Although 6-gingerol and rhapontin also inhibited hemolysis as barbaloin did (Figures 
5.4, 5.5 and 5.6), they did not protect Ca^^-ATPase activity. The present results 
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suggest that the protective mechanism of barbaloin against membrane damage might 
be due to its protective actions on membrane proteins as revealed in the recovery of 
the ATPase activity. 
5.3.4 Na+/K+-ATPase protection assay 
Apart from Ca^^-ATPase assay, Na+/K+-ATPase assay was also performed. In the 
Na"7K+-ATPase assay, /BHP and hemin generate free radicals that cross-l ink proteins 
and inactivate RBC membrane Na+/K+-ATPase. The test compounds with antioxidant 
effects would be able to protect the activity of Na+/K+-ATPase. 
In this assay, rhapontin showed positive effect. It has a weaker potency than trolox in 
recovering the ATPase activity (Table 5.8). Rhapontin is capable of forming stable 
phenoxyl radicals due to delocalization of electrons into the benzene ring structure 
(Cao et al” 2003), so it may neutralize free radicals and protect Na+/K+-ATPase from 
free radical attack. Results in hemolysis assay and Na"VK+-ATPase assay revealed that 
rhapontin possessed both radical scavenging and ATPase protection abilities. 
Although 6-gingerol and barbaloin inhibited hemolysis as rhapontin did (Figures 5.4, 
5.5 and 5.6), they did not protect Na+/K+-ATPase activity. 
Since the reduced state of sulfhydryl groups on ATPase is involved in the activity of 
the enzyme and sulfhydryl groups are prone to free radical attack, it is necessary to 
find out whether the test compounds inhibit ROS attack on protein sulfhydryl groups. 
Sulfhydryl group protection assay was thus performed after the ATPase protection 
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assay to determine whether sulfhydryl group protection contributes to the antioxidant 
effects of the test compounds. 
5.3.5 Sulfhydryl group protection assay 
After ATPase protection assays, sulfhydryl group assay was performed to study the 
protective mechanism of the test compounds at a greater depth. /BHP and hemin 
served as the oxidants in this assay. They generated free radicals to oxidize the RBC 
membrane. The sulfhydryl groups on the membrane proteins would thus be subjected 
to oxidation or cross-linkage (Marks et al., 1996). Although sulfhydryl group 
oxidation could take place in the presence of high concentration of tBEF alone, both 
rBHP and hemin were applied in this assay. This was to keep the consistency of 
oxidation system used, so that the action mechanisms of the test compounds could be 
made comprehensible. I f the test compounds possess positive effect in this assay, 
sulfhydryl groups could be preserved in the reduced state and could react with DTNB 
to produce a colored compound. Barbaloin showed positive results in this sulhydryl 
group protection assay (Figure 5.25) suggesting that it can protect sulfhydryl groups 
of RBC membrane against free radical attack. The percentage of protein sulfhydryl 
group recovery was compared against trolox, the positive control. Barbaloin was 
determined to have a stronger potency than trolox (Table 5.10). 
It was found that rhapontin was effective in protecting Na+/K+-ATPase but not Ca^ "^ -
ATPase, whereas barbaloin was effective in protecting Ca "^^ -ATPase but not Na+/K+-
ATPase. However, it is still uncertain about the cause of different protective effects of 
rhapontin and barbaloin towards the two ATPases at this stage. A possible 
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explanation is that Ca^^-ATPase is more sensitive to sulfhydryl group oxidation than 
Na+/K+-ATPase，so a sulfhydryl group protector such as barbaloin could protect Ca^ ""-
ATPase from oxidative stress. One of the studies has shown that a sulfhydryl group 
modifying reagent N-ethylmaleimide (NEM) is able to inhibit Ca '^^ -ATPase, as 
sulfhydryl group is essential to the activity of Ca^ -^ATPase (Takahashi and 
Yamaguchi, 1994). Therefore, inactivation of Na+/K+-ATPase by /BHP/hemin may be 
caused by mechanisms other than sulfhydryl group oxidation and rhapontin is 
probably matched to provoke this effect. This showed that antioxidants have different 
specific antioxidant properties. 
Results in hemolysis assay and Ca^^-ATPase assay reveal that barbaloin possesses 
both radical scavenging and Ca^^-ATPase protective effects. Together with the results 
in the sulfhydryl group assay, it may be concluded that protection of the protein 
sulfhydryl group by barbaloin might lead to the preservation of the Ca '^^ -ATPase 
activity and the RBC membrane integrity. Although rhapontin possesses similar 
antioxidative characteristics as barbaloin, it has no effect in the sulfhydryl group 
protection assay, suggesting that rhapontin does not inhibit hemolysis through 
sulfhydryl group protection. Moreover, 6-gingerol does not show protection to either 
ATPases or protein sulfhydryl groups. Therefore, its protective effects on hemolysis 
cannot be attributed to these mechanisms. This indicates that 6-gingerol might not be 
able to inhibit protein cross-linkage. In summary, barbaloin has a wider aspect of 
antioxidant abilities than rhapontin and 6-gingerol. After the assays related to the 
RBC were performed, the test compounds' actions on another important blood 
component, LDL, were investigated. 
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5.3.6 Chapter summary 
6-Gingerol, barbaloin and rhapontin possess antioxidative effects, but their protective 
mechanisms vary. 6-Gingerol inhibited hemolysis and RBC membrane lipid 
peroxidation (Figure 5.4 and 5.9), but it could neither reduce ATPase inhibition nor 
protect protein sulfhydryl groups in RBC membranes (Tables 5.5, 5.7 and 5.9). This 
indicates that it may inhibit free radical propagation after free radical attack. 
Rhapontin protects RBC from lysis (Figure 5.6)，protects RBC membrane against 
lipid peroxidation (Figure 5.11) and protects Na+/K+-ATPase from inhibition (Figure 
I 
5.21), but it neither reduces Ca -ATPase inhibition (Table 5.5) nor protects protein 
sulfhydryl group in the membrane (Table 5.9). When compared to 6-gingerol, it 
possesses a wider scope of protection. Barbaloin inhibited hemolysis and RBC 
membrane lipid peroxidation (Figure 5.5 and 5.10). It also reduced Ca^ -^ATPase 
inhibition (Figure 5.17) and protected protein sulfhydryl group in membrane (Figure 
5.25), but it did not reduce Na+/K+-ATPase inhibition (Table 5.7). Thus, it has the 
widest range of antioxidant abilities among the compounds tested. 
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Chapter 6 Lipid peroxidation inhibition assay of 
LDL: results and discussion 
6.1 Introduction 
Apart from RBC, LDL is another blood component prone to oxidant attack. LDL 
oxidation is the basis of some free radical-derived diseases. Under oxidative stress, 
oxidized LDL accumulates causing inflammation of arterial wall. This eventually 
leads to atherosclerosis. Protection of LDL from oxidation delays the progress of 
atherosclerosis. Therefore, the antioxidative effects of the test compounds on LDL 
were evaluated through lipid peroxidation inhibition assays. Two oxidants, AAPH and 
hemin, were applied. The assays were carried out according to the protocols described 
in the Materials and methods chapter. 
6.2 Results 
The results for the AAPH-induced lipid peroxidation inhibition assay of LDL are 
summarized in Figures 6.1 to 6.6，and Tables 6.1 to 6.2. Figure 6.1 and 6.2 show the 
effect of variation in incubation time and different concentrations of AAPH on 
AAPH-induced lipid peroxidation of LDL respectively. From the results, the optimal 
assay conditions were determined. Figure 6.3 demonstrates the effects of the positive 
control, trolox. Its IC50 was determined to be 40.9|aM. Figure 6.4 shows the effects of 
6-gingerol. Its IC50 was found to be 19.1)^M. Figure 6.5 shows the effects of barbaloin. 
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Its IC50 was determined to be 142.4|_iM. Figure 6 .6 demonstrates the effects of 
rhapontin. Its IC50 was found to be 14.1^M. The three compounds were able to 
protect LDL from lipid peroxidation in a dose-dependent manner. Table 6.1 displays 
the results of the other test compounds. They did not exhibit any inhibitory effects on 
LDL lipid peroxidation at the concentrations tested in the presence of AAPH. The 
relative potencies of the test compounds with positive effects in this assay are shown 
in Table 6.2. 
The results for the hemin-induced lipid peroxidation inhibition assay of LDL are 
summarized in Figures 6.7 to 6.12，and Tables 6.3 to 6.4. Figure 6.7 and 6.8 show the 
effect of variation in incubation time and different concentrations of hemin on hemin-
induced lipid peroxidation of LDL respectively. From the results, the optimal assay 
conditions were determined. Figure 6.9 demonstrates the effects of the positive 
control, trolox. Its IC50 was determined to be 0.195|aM. Figure 6.10 shows the effects 
of 6-gingerol. Its IC50 was found to be 0.054j^M. Figure 6.11 demonstrates the effects 
of barbaloin. Its IC50 was determined to be 2.845jj,M. Figure 6 . 1 2 shows the effects of 
rhapontin. Its IC50 was found to be 0.104|j,M. These three compounds exhibited 
positive effects towards LDL oxidation produced by hemin in a dose dependent 
manner. Table 6.3 displays the results of the other test compounds. They did not 
exhibit any inhibitory effects on LDL lipid peroxidation at the concentrations tested in 
the presence of hemin. The relative potencies of the test compounds with positive 
effects in this assay are shown in Table 6.4. 
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Figure 6.1 The time-dependent AAPH-induced lipid peroxidation of LDL. This is a 
preliminary experiment for obtaining the appropriate incubation time to be applied in 
subsequent assays. The assay was conducted with lOmM AAPH. Results are 
expressed as the fluorescent unit of TEARS produced in one experiment. A.U.= 
arbitary unit. 
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Figure 6.2 The dose-dependent AAPH-induced lipid peroxidation of LDL. This is a 
preliminary experiment for obtaining the appropriate concentration of AAPH to be 
applied in subsequent assays. LDL was incubated with AAPH for 2 h. Results are 
expressed as the fluorescent unit of TBARS produced in one experiment. A.U.= 
arbitary unit. 
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Figure 6.3 The inhibitory effect of trolox on AAPH-induced lipid peroxidation of 
LDL. The assay was conducted with 20mM AAPH, in the absence (control) or 
presence of various concentrations of trolox. Degree of lipid peroxidation inhibition is 
expressed as percentage of control. Data represent mean 土 S.D. in four independent 
experiments. 
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Figure 6.4 The inhibitory effect of 6-gingerol on AAPH-induced lipid peroxidation 
of LDL. The assay was conducted with 20mM AAPH, in the absence (control) or 
presence of various concentrations of 6-gingerol. Degree of lipid peroxidation 
inhibition is expressed as percentage of control. Data represent mean 士 S.D. in four 
independent experiments. 
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Figure 6.5 The inhibitory effect of barbaloin on AAPH-induced lipid peroxidation of 
LDL. The assay was conducted with 20mM AAPH, in the absence (control) or 
presence of various concentrations of barbaloin. Degree of lipid peroxidation 
inhibition is expressed as percentage of control. Data represent mean 士 S.D. in four 
independent experiments. 
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Figure 6.6 The inhibitory effect of rhapontin on AAPH-induced lipid peroxidation of 
LDL. The assay was conducted with 20mM AAPH, in the absence (control) or 
presence of various concentrations of rhapontin. Degree of lipid peroxidation 
inhibition is expressed as percentage of control. Data represent mean 士 S.D. in four 
independent experiments. 
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Figure 6.7 The time-dependent hemin-induced lipid peroxidation of LDL. This is a 
preliminary experiment for obtaining the appropriate incubation time to be applied in 
subsequent assays. The assay was conducted with 1 |aM hemin. Results are expressed 
as the fluorescent unit of TEARS produced in one experiment. A.U. = arbitary unit. 
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Figure 6.8 The dose-dependent hemin-induced lipid peroxidation of LDL. This is a 
preliminary experiment for obtaining the appropriate concentration of hemin to be 
applied in subsequent assays. LDL was incubated with hemin for 2 h. Results are 
expressed as the fluorescent unit of TEARS produced in one experiment. A .U.= 
arbitary unit. 
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Figure 6.9 The inhibitory effect of trolox on hemin-induced lipid peroxidation of 
LDL. The assay was conducted with 1 |_iM hemin, in the absence (control) or presence 
of various concentrations of trolox. Degree of lipid peroxidation inhibition is 
expressed as percentage of control. Data represent mean 士 S.D. in four independent 
experiments. 
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Figure 6.10 The inhibitory effect of 6-gingerol on hemin-induced lipid peroxidation 
of LDL. The assay was conducted with l|_iM hemin, in the absence (control) or 
presence of various concentrations of 6-gingerol. Degree of lipid peroxidation 
inhibition is expressed as percentage of control. Data represent mean 土 S.D. in four 
independent experiments. 
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Figure 6.11 The inhibitory effect of barbaloin on hemin-induced lipid peroxidation 
of LDL. The assay was conducted with l^iM hemin, in the absence (control) or 
presence of various concentrations of barbaloin. Degree of lipid peroxidation 
inhibition is expressed as percentage of control. Data represent mean 士 S.D. in four 
independent experiments. 
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Figure 6.12 The inhibitory effect of rhapontin on hemin-induced lipid peroxidation 
of LDL. The assay was conducted with 1|j,M hemin, in the absence (control) or 
presence of various concentrations of rhapontin. Degree of lipid peroxidation 
inhibition is expressed as percentage of control. Data represent mean 士 S.D. in four 
independent experiments. 
1 3 1 
Table 6.1 The inhibitory effects of different compounds on AAPH-induced lipid 
peroxidation of LDL. 
Test compounds Maximum conc. tested Effect 
Aloe-emodin 50 ^iM Inactive 
Chrysophanol 50 |iM Inactive 
Deoxyrhapontin 500 jj.M Inactive 
Rhein 1000 }iM Inactive 
The concentrations shown in the table are the maximum final concentrations of the 
compounds. 
Table 6.2 The relative potencies of test compounds on the inhibition of AAPH-
induced lipid peroxidation of LDL. 
Test compounds IC^ Relative potency 
• Trolox 40.9 laM 1 
6-Gingerol 19.1 |iM ^ 
Barbaloin 142.4 [ M ^ 
Rhapontin 14.1 pM ^ 
Their IC50 values are compared against trolox, which is the positive control. Relative 
potency = IC50 of trolox / IC50 of compound. 
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Table 6.3 The inhibitory effects of different compounds on hemin-induced lipid 
peroxidation of LDL. 
Test compounds Maximum conc. tested Effect 
Aloe-emodin 50 |j.M Inactive 
Chrysophanol 50 Inactive 
Deoxyrhapontin 500 [iM Inactive 
Rhein 1000 )iM Inactive 
The concentrations shown in the table are the maximum final concentrations of the 
compounds. 
Table 6.4 The relative potencies of test compounds on the inhibition of hemin-
induced lipid peroxidation of LDL. 
Test compounds IC50 Relative potency 
Trolox 0.195 [ l M 1 
6-Gingerol 0.054 
Barbaloin 2.845 \xM 0.069 
Rhapontin 0.104 
Their IC50 values are compared against trolox, which is the positive control. Relative 
, potency = IC50 of trolox / IC50 of test compounds. 
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6.3 Discussion 
After studying the compounds' abilities to protect RBC and its components against 
oxidative stress, the abilities of these compounds to inhibit LDL oxidation were also 
investigated to evaluate their potentials in preventing diseases linked to the oxidation 
of LDL. AAPH and hemin were applied as the oxidants in these assays. 
In order to understand the reason for performing AAPH-induced and hemin-induced 
lipid peroxidation inhibition assay of LDL, it is necessary to observe the difference 
between the two oxidants used in these two assays. RBC could be lysed when extreme 
oxidative stress arises and hemoglobin will be released. Hemoglobin is also released 
from RBC as a natural process during RBC degradation. Hemoglobin releases heme 
during degradation (Marks et al” 1996). Heme could be oxidized to form hemin. 
Hemin is an oxidant that may appear in blood. Therefore, the LDL assay using hemin 
as the oxidant was performed. On the other hand, AAPH is an artificial oxidant. It is 
applied in the present study since it is a reliable radical source, such that an effective 
radical scavenger can be identified in the assay. 
Both hemin and AAPH were used as oxidants in the assay in order to investigate the 
two possible protective mechanisms of the test compounds. AAPH initiates chain 
reaction of lipid peroxidation as it can become radical itself or form peroxyl radical in 
the presence of oxygen, whereas hemin propagates chain reaction by catalyzing the 
formation of lipid peroxyl radicals from the existing lipid hydroperoxides in LDL. 
Existing peroxide in LDL (LOOH) is converted by hemin to peroxyl radical (LOO*) 
which propagates lipid peroxidation. 
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LOOK — LOO* 
I f the test compounds exhibit protection of LDL against AAPH-induced lipid 
peroxidation, they might either scavenge AAPH radicals or scavenge lipid peroxyl 
radicals to terminate the chain reaction. In the case of hemin-catalyzed lipid 
peroxidation, the compounds could only act as chain-breaking antioxidant by 
scavenging lipid peroxyl radicals. The effects of the test compounds were studied 
under both oxidation systems to evaluate their antioxidative mechanisms, whether 
they serve as chain-breaking antioxidants, or as free radical scavengers, or both. 
Regarding the AAPH-induced lipid peroxidation of LDL, peroxyl radicals were 
generated. The resulting peroxides started to propagate the chain reaction. MDA 
produced by lipid peroxidation formed colored complex with TBA, and fluorescence 
was measured. 6-Gingerol, barbaloin and rhapontin were demonstrated to exhibit 
inhibitory actions in this assay. When compared to trolox, 6-gingerol and rhapontin 
had a smaller IC50 values, whereas barbaloin had a higher one. This means that 6 -
gingerol and rhapontin are more effective in protecting LDL from lipid peroxidation. 
These compounds are able to inhibit LDL oxidation and may have potential 
applications in atherosclerosis and other related diseases. This awaits further in vivo 
studies. 
6-Gingerol, barbaloin and rhapontin were demonstrated to exhibit positive results in 
the hemin-induced lipid peroxidation inhibition assay of LDL. Their results were 
compared against the positive control, trolox. The IC50 values of 6-gingerol and 
rhapontin were smaller than that of trolox, whereas barbaloin was larger. When 
comparing 6-gingerol and rhapontin, the former had a smaller IC50 values. In other 
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words, 6-gingerol has the strongest lipid peroxidation inhibitory effect, followed by 
rhapontin, and then barbaloin. These compounds might possess the ability to scavenge 
lipid peroxyl radicals and reduce the degree of LDL oxidation. Although 6-gingerol 
has previously been reported to possess antioxidative activity (Kikuzaki et al,, 1993; 
Aeschbach et al.’ 1994)，to my knowledge the present study is the first report to 
demonstrate its antioxidative effects in more physiological systems on human blood 
components, RBC and LDL, and the results may have clinical implications on free 
radical-derived diseases. 
From the results of these two assays, it was found that 6-gingerol and rhapontin 
scavenge lipid peroxyl radicals, and they have stronger potencies than trolox. They 
are chain-breaking antioxidants. Barbaloin also possesses antioxidative abilities but it 
has weaker potency than trolox. Its radical scavenging ability is better than its chain-
breaking ability, since its potency in comparison to trolox is comparatively higher in 
the assay with AAPH. 
When the active compounds are compared between the AAPH-induced and the 
hemin-induced lipid peroxidation of LDL, it is found that the IC50 values of the test 
compounds are much smaller in the hemin-induced assay. This may be due to the low 
level of lipid peroxides exists in the LDL for the chain reaction initiation. 
Nevertheless, the test compounds with positive effects possess significant antioxidant 
properties towards lipids. 
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Chapter 7 General discussion 
XOD plays a significant role in hyperuricemia and ischemia-reperfUsion injury. 
Compounds with inhibitory actions on XOD would contribute towards the alleviation 
of one or both of these conditions. Deoxyrhapontin, a compound isolated from 
rhubarb root, was found to have the ability in inhibiting XOD activity. From our 
results, the mode of inhibition of deoxyrhapontin was of mixed type and its inhibitory 
effect was reversible in nature. The present results therefore suggest that the 
traditional use of Rheum species in the treatment of gout and other related clinical 
syndromes may have its scientific basis on the XOD inhibitory compounds they 
contain. More studies are required before it could be applied clinically, such as in vivo 
data and toxicity profile. It was also found that deoxyrhapontin did not possess 
antioxidant effect. 
The lipid peroxidation inhibition assay using mouse liver microsomes was performed 
to study the compounds regarding their antioxidative strength. As RBC are exposed to 
oxidative stress constantly, therefore AAPH-induced hemolysis assay was performed 
to evaluate the compounds' antioxidative ability. It was found that 6-gingerol, 
barbaloin and rhapontin possessed positive effects, meaning that they are able to 
scavenge radicals and inhibit hemolysis. The positive effects of the test compounds in 
the AAPH-induced hemolysis assay prompted the development of other assays related 
to the components of RBC for detailed studies of the compounds' antioxidant effects 
on the RBC. 
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Factors contributing to hemolysis include membrane lipid peroxidation, protein 
oxidation, ion influx and depletion of antioxidants. Therefore, assays relating to these 
aspects were performed to evaluate the test compounds' antioxidative ability on 
hemolysis. The assays include lipid peroxidation inhibition assay, protein sulfhydryl 
group protection assay and ATPase protection assays. They aim at investigating 
whether the test compounds could inhibit hemolysis through inhibition of lipid 
peroxidation, inhibition of protein oxidation or protection of ion transport vehicles. 
Results in these assays implied the antioxidant mechanisms of the test compounds and 
are summarized as follows. In RBC membrane lipid peroxidation assay, 6-gingerol, 
barbaloin and rhapontin exhibited positive effects (Figures 5.9, 5.10 and 5.11). This 
indicates that these compounds might possess the ability to scavenge lipid peroxyl 
radicals and reduce the degree of RBC membrane disintegration through lipid 
peroxidation inhibition. The results of protein sulfhydryl group protection assay and 
ATPase assays (Figures 5.17 and 5.25) indicate that barbaloin was able to protect 
membrane protein and Ca2+-ATPase through protein sulfhydryl group protection. 
Rhapontin showed positive results in Na+/K+-ATPase assay (Figure 5.21) but not 
sulfhydryl group protection assay (Table 5.9)，meaning it probably protects Na+/K+-
ATPase through other mechanisms instead of protein sulfhydryl group protection. 
Taking all the results regarding RBC into consideration, it could be concluded that 
prevention of membrane lipid peroxidation is important to protect RBC against 
hemolysis. This is due to the fact that peroxidation of membrane does not only distort 
the lipid bilayer array, the resulting peroxyl radicals also cross-linked transmembrane 
proteins and intracellular proteins, thus destroying the complete cellular structure 
eventually (Marks et al” 1996). Although 6-gingerol and rhapontin have more 
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restricted aspects in their protection mechanisms as compared to barbaloin, they could 
still demonstrate significant protective effects against hemolysis through lipid 
peroxidation inhibition. This indicates the significance of lipid peroxidation inhibition. 
For LDL lipid peroxidation assay, the potency of 6-gingerol, barbaloin and rhapontin 
were directly proportional to their protective effects towards LDL and their capability 
to act against atherosclerosis. In view of the results of antioxidant assays, the three 
compounds might possess the potential to offer protection against ROS-derived 
diseases. Among the test compounds in the present study, none of them possess both 
XOD inhibitory and antioxidant activities. Some of them were found to possess either 
one of the activities and some of them possess neither one of the activities. 
With reference to the compounds' relative potency against trolox in all assays, the 
antioxidative characteristics of barbaloin, 6-gingerol and rhapontin are identified as 
follows. Barbaloin has a lower potency than trolox in hemin-induced lipid 
peroxidation of LDL (Table 6.4) and it has no effect in mouse liver microsome lipid 
peroxidation (Table 4.1)，meaning that barbaloin is a poor chain-breaking antioxidant. 
Barbaloin has greater protective effect than trolox in AAPH-induced hemolysis assay 
(Table 5.2), lipid peroxidation inhibition assay of RBC membrane (Table 5.4) and 
sulfhydryl group protection assay (Table 5.10). This indicates that barbaloin is able to 
scavenge AAPH and rBHP radicals to inhibit lipid peroxidation and protein 
degradation. Moreover, 6-gingerol is unable to protect protein sulfhydryl groups and 
ATPases from rBHP radical attack (Table 5.5, 5.7 and 5.9)，suggesting that it is a poor 
rBHP radical scavenger. It has low activity in AAPH-induced hemolysis assay (Table 
5.2), meaning that it has low ability in scavenging AAPH-derived radicals. 6-Gingerol 
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has higher potency than trolox in all lipid peroxidation assays (Tables 4.2，5.4，6.2 and 
6.4)，meaning that it is a strong chain-breaking antioxidant. Furthermore, rhapontin 
has higher potency then trolox in all lipid peroxidation assays, but it is a less potent 
chain-breaking antioxidant when compared to 6-gingerol. Rhapontin is more potent 
than 6-gingerol in all AAPH-induced reactions (Tables 5.2 and 6.2)，which means that 
it is a better AAPH-derived radical scavenger. 
Most of the compounds showing negative effects on XOD inhibition and antioxidant 
assays are the anthraquinones. However, it should be noted that one of the factors 
which contributes to their negative effects in these assays is their poor solubility. 
Barbaloin is an exception. Apart from the anthraquinone structure, barbaloin also 
contains a glycosidic moiety which increases its solubility in water. Therefore 
solutions with higher concentrations of the compound could be prepared. Solubility is 
a factor that might contribute to the detection of activity among the anthraquinones. 
This example illustrates the importance of solubility of the test compounds in 
determining their usefulness, so the solubility issue should be considered in any drug 
screening exercise. 
From the results of this study, it is found that each active component of CMM has a 
unique biological significance. As an extract of CMM is usually composed of a 
number of active components, it may have a number of therapeutic actions. Therefore, 
CMM are sometimes suggested to possess bidirectional regulatory effects, which is an 
advantage over western drugs. This is due to the fact that effects exerted by two 
compounds are able to complement each other to give a greater combined effect. For 
example, the stilbene components in rhubarb can act together in a complementary 
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manner with deoxyrhapontin inhibiting XOD on the one hand and rhapontin 
attenuating oxidative stress on the other, thus achieving both ends of urate-lowering 
and antioxidant supplementation. Another synthesis from the present study is the 
possible combined usage of ginger and aloe. 6-Gingerol from ginger and barbaloin 
from aloe were demonstrated to preferentially protect lipids and proteins respectively. 
Their combination provides a wider scope of antioxidative effects which might 
increase their abilities in the protection against ROS-derived diseases such as aging 
and atherosclerosis. They may find potential applications in health products such as 
cosmetics and drinks — "ginger juice aloe drinks". 
In this project, the XOD inhibitory and antioxidant effects of a number of CMM-
derived compounds and their mechanisms of action were evaluated. The results may 
provide some information on the structure-activity relationship for these compounds, 
which could be useful for future drug development for diseases involving abnormal 
antioxidant and pro-oxidant conditions. Since the results obtained are limited to in 
vitro conditions, further studies are required to examine the safety and efficacy of 
these compounds. In vivo experiments, toxicity determination, and finally clinical 
trials have to be performed to substantiate the clinical potentials of these compounds. 
1 4 1 
References 
Aeschbach R.，Loliger J., Scott B.C., Murcia A., Butler L, Halliwell B.，Aruoma O.I. 
(1994) Antioxidant actions of thymol, carvacrol, 6-gingerol, zingerone and 
hydroxytyrosol. Food Chem Toxicol 32: 31-36 
Alberts B.，Bray D.，Lewis J., Raff M.，Roberts K.，Watson J. (1994) Molecular 
biology of the cell, ed. New York: Garland Publishing. 
Al-Jobore A., Roufogalis B.D. (1981) Influence of EGTA on the apparent Ca^ "^  
affinity of Mg2+-dependent, Ca^^-stimulated ATPase in the human erythrocyte 
membrane. Biochim Biophys Acta 645: 1-9 
Ames B.N.，Cathcart R.，Schwiers E.，Hochstein P. (1981) Uric acid provides an 
antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a 
hypothesis. Proc Natl Acad Sci USA 78: 6858-6862 
Aucamp J., Caspar A., Hara Y.’ Apostolides Z. (1997) Inhibition of xanthine oxidase 
by catechins from tea {Camellia sinensis). Anticancer Res 17: 4381-4385 
Basaga H., Poli G.，Tekkaya C.’ Aras I. (1997) Free radical scavenging and 
antioxidative properties of 'silibin' complexes on microsomal lipid peroxidation. Cell 
Biochem Funct 15: 27-33 
1 4 2 
Bowler R.P., Nicks M.，Olsen D.A., Thogersen LB., Valnickova Z.，Hojrup P., 
Franzusoff A., Enghild J.J.’ Crapo J.D. (2002) Furin proteolytically processes the 
heparin-binding region of extracellular superoxide dismutase. J Biol Chem 277: 
16505-16511 
Camejo G.，Halberg C.，Manschik-Lundin A., Hurt-Camejo E.，Rosengren B., Olsson 
H.，Hansson G.I.，Forsberg G.B., Ylhen B. (1998) Hemin binding and oxidation of 
lipoproteins in serum: mechanisms and effect on the interaction of LDL with human 
macrophages. J Lipid Res 39: 755-766 
Canas P.E. (1999) The role of xanthine oxidase and the effects of antioxidants in 
ischemia reperfusion cell injury. Acta Physiol Pharmacol Ther Latinoam 49: 13-20 
Cao H.，Pan X.，Li C.’ Zhou C., Deng F.，Li T. (2003) Density functional theory 
calculations for resveratrol Bioorg Med Chem Lett 13: 1869-1871 
Chan W.S., Wen P.C., Chiang H.C. (1995) Structure-activity relationship of caffeic 
acid analogues on xanthine oxidase inhibition. Anticancer Res 15: 703-708 
Chang H.Y., Pan W.H., Yeh W.T., Tsai K.S. (2001) Hyperuricemia and gout in 
Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J 
Rheumatol 28: 1640-1646 
Chang W.S., Chang Y.H., Lu FJ.，Chiang H.C. (1994) Inhibitory effects of phenolics 
on xanthine oxidase. Anticancer Res 14: 501-506 
1 4 3 
Engerson T.D., McKelvey T.G., Rhyne D.B., Boggio E.B.，Snyder S J.，Jones H.P. 
(1987) Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues. J 
Clin Invest 79: 1564-1570 
Fernandez L.’ Carrasco-Chaumel E.，Serafin A., Xaus C., Grande L.，Rimola A., 
Rosello-Catafau J.，Peralta C. (2004) Is ischemic preconditioning a useful strategy in 
steatotic liver transplantation? Am J Transplant 4: 888-899 
Haest C.W.M., Plasa G.，Kamp D., Deuticke B. (1978) Spectrin as a stabilizer of the 
phospholipid asymmetry in the human erythrocyte membrane. Biochim Biophys Acta 
509:21-32. 
Harris M.D.，Siegel L.B., Alloway J.A. (1999) Gout and hyperuricemia. Am Fam 
Physician 59: 925-934 
Higuchi A., Yonemitsu K.，Koreeda A., Tsunenari S. (2003) Inhibitory activity of 
epigallocatechin gallate (EGCg) in paraquat-induced microsomal lipid peroxidation—a 
mechanism of protective effects of EGCg against paraquat toxicity. Toxicology 183: 
143-149 
Horiuchi H., Ota M.，Nishimura S.’ Kaneko H.’ Kasahara Y.，Ohta T.’ Komoriya K. 
(2000) Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. 
Life Sci 66:2051-2070 
1 4 4 
Hotter G.，Closa D.，Pi R，Rosello-Catafau J., Bulbena 0.，Badosa F., Femandez-Cruz 
L.，Gelpi E. (1994) Arachidonate metabolism in ischemia-reperfusion associated with 
pancreas transplantation. J Lipid Mediat Cell Signal 9: 135-143 
Jansson P.J.，Asplund K.U., Makela J.C., Lindqvist C.，Nordstrom T. (2003) Vitamin 
C (ascorbic acid) induced hydroxyl radical formation in copper contaminated 
household drinking water: role of bicarbonate concentration. Free Radic Res 37: 901-
905 
Jimenez I., Garrido A.，Bannach R.，Gotteland M.，Speisky H. (2000) Protective 
effects of boldine against free radical-induced erythrocyte lysis. Phytother Res 14: 
339-343 
Jorgensen P.L., Hakansson K.O., Karlish SJ.D. (2003) Structure and mechanism of 
Na，K-ATPase: functional sites and their interactions. Annu Rev Physiol 65: 817-849 
Kallner A. (1975) Determination of phosphate in serum and urine by a single step 
malachite-green method. Clin Chim Acta 59: 35-39 
Kenney I.J. (1991) Renal sonography in long standing Lesch-Nyhan syndrome. Clin 
Radiol 43: 39-41 
Kikuzaki H., Nakatani N. (1993) Antioxidant effects of some ginger constituents. J 
Food Sci 58: 1407-1410 
1 4 5 
Kim D.H., Park E.K., Bae E.A., Han MJ. (2000) Metabolism of rhaponticin and 
chrysophanol 8-0-beta-D-glucopyranoside from the rhizome of Rheum Undulatum by 
human intestinal bacteria and their anti-allergic actions. Biol Pharm Bull 23: 830-833 
K i m Y.M., Yun J., Lee C.K., Lee H.，Min K.R.，Kim Y. (2002) Oxyresveratrol and 
hydroxystilbene compounds. Inhibitory effect on tyrosinase and mechanism of action. 
J Biol Chem 277:16340-16344 
Kirschbaum B. (2001) Renal regulation of plasma total antioxidant capacity. Med 
Hypotheses 56: 625-629 
Knight J.A. (2000) The biochemistry of aging. Adv Clin Chem 35: 1-62 
Kong L.D.，Cai Y.，Huang W.W., Cheng C.H.，Tan R.X. (2000) Inhibition of xanthine 
oxidase by some Chinese medicinal plants used to treat gout. J Ethnopharmacol 73: 
199-207 
Kong L.D.，Zhang Y.，Pan X.，Tan R.X., Cheng C.H. (2000) Inhibition of xanthine 
oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. 
Cell Mol Life Sci 57: 500-505 
Larson R.A. (1997) Naturally occurring antioxidants. Boca Raton: Lewis Publishers. 
Lee K.H. (2000) Research and future trends in the pharmaceutical development of 
medicinal herbs from Chinese medicine. Public Health Nutr 3: 515-522 
1 4 6 
Lehninger A丄.，Nelson D丄.，Cox M.M. (2000) Lehninger principles of biochemistry, 
3rd ed. New York: Worth Publishers. 
Li C.L., Ye Y.W. (1981) Effects of rhapontin of Rheum hotaoense on serum lipid and 
lipoprotein levels (serum). Yao Xue Xue Bao 16: 699-702 
Li H.，Meng J.C., Cheng C.H., Higa T.，Tanaka J.，Tan R.X. (1999) New guaianolides 
and xanthine oxidase inhibitory flavonols from Ajania fruticulosa. J Nat Prod 62: 
1053-1055 
Lin K.C., Tsao H.M., Chen C.H., Chou P. (2004) Hypertension was the major risk 
factor leading to development of cardiovascular diseases among men with 
hyperuricemia. J Rheumatol 31: 1152-1158 
Liu G.T., Zhang T.M., Wang B.E., Wang, Y.W. (1992) Protective action of seven 
natural phenolic compounds against peroxidative damage to biomembranes. Biochem 
Pharmacol 43: 147-152. 
Lowry O.H., Rosebrough N.J., Farr A.L., Randall RJ. (1951) Protein measurement 
with the Folin phenol reagent. J Biol Chem 193: 265-275 
Marks D.B., Marks A.D.，Smith C.M. (1996) Basic medical biochemistry: a clinical 
approach. Baltimore: Williams and Wilkins. 
1 4 7 
Matsuda H.，Kageura T.，Morikawa T.’ Toguchida L, Harima S.，Yoshikawa M. (2000) 
Effects of stilbene constituents from rhubarb on nitric oxide production in 
lipopolysaccharide-activated macrophages. Bioorg Med Chem Lett 10: 323-327 
Matsuda H.’ Morikawa T.，Toguchida I.，Park J.Y., Harima S.，Yoshikawa M. (2001) 
Antioxidant constituents from rhubarb: structural requirements of stilbenes for the 
activity and structures of two new anthraquinone glucosides. Bioorg Med Chem 9: 
41-50 
Matteucci E.，Cocci F.，Pellegrim L.’ Gregori G.，Giampietro 0. (1995) Measurement 
of ATPase in red cells: setting up and validation of a highly reproducible method. 
Enzyme Protein 48:105-119 
Medvedev A.E., Ivanov A.S., Kamyshanskaya N.S.，Kirkel A.Z., Moskvitina T.A., 
Gorkin V.Z., Li N.Y., Marshakov V.Y. (1995) Interaction of indole derivatives with 
monoamine oxidase A and B. Studies on the structure-inhibitory activity relationship. 
Biochem Mol Biol Int 36: 113-122 
Messina MJ. (1991) Oxidative stress and cancer: methodology application for human 
studies. Free Radic Biol Med 10: 177-184 
Miller Y.I., Felikman Y.，Shaklai N. (1995) The involvement of low-density 
lipoprotein in hemin transport potentiates peroxidative damage. Biochim Biophys 
Acta 1272: 119-127 
1 4 8 
Miller Y.I.，Smith A., Morgan W.T., Shaklai N. (1996) Role of hemopexin in 
protection of low-density lipoprotein against hemoglobin-induced oxidation. 
Biochemistry 35: 13112-13117 
Mireles L.C., Lum M.A.，Dennery P.A. (1999) Antioxidant and cytotoxic effects of 
bilirubin on neonatal erythrocytes. Pediatr Res 45: 355-362 
Moriwaki Y.，Yamamoto T.，Higashino K. (1999) Enzymes involved in purine 
metabolism. Histol Histopathol 14: 1321-1340 
Nakao K., Shimizu R.，Kubota H.，Yasuhara M.，Hashimura Y.，Suzuki T.，Fujita T., 
Ohmizu H. (1998) Quantitative structure-activity analyses of novel 
hydroxyphenylurea derivatives as antioxidants. Bioorg Med Chem 6: 849-868 
Nieto F.J., Iribarren C.，Gross M.D., Comstock G.W., Cutler R.G. (2000) Uric acid 
and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 148: 
131-139 
Olinescu R.’ Smith T. (2002) Free radicals in medicine. Hungtington, New York: 
Nova Science Publishers, Inc. 
Osada Y.，Tsuchimoto M.，Fukushima H.，Takahashi K.，Kondo S., Hasegawa M., 
Komoriya K. (1993) Hypouricemic effect of the novel xanthine oxidase inhibitor, 
TEI-6720, in rodents. Eur J Pharmacol 241: 183-188 
1 4 9 
Ou B.，Huang D.，Hampsch-Woodill M., Flanagan J.A., Deemer E.K. (2002) Analysis 
of antioxidant activities of common vegetables employing Oxygen Radical 
Absorbance Capacity (ORAC) and Ferric Reducing Antioxidant Power (FRAP) 
assays: a comparative study. J Agric Food Chem 50: 3122-3128 
Owen P.L., Johns T. (1999) Xanthine oxidase inhibitory activity of northeastern 
North American plant remedies used for gout. J Ethnopharmacol 64: 149-160 
Reinila M.，MacDonald E.，Salem N., Linnoila M.，Trams E.G. (1982) Standardized 
method for the determination of human erythrocyte membrane adenosine 
triphosphatases. Anal Biochem 124: 19-26 
Rice-Evans C.，Halliwell B.’ Lunt G.G. (1995) Free radicals and oxidative stress: 
environment, drugs and food additives. London: Portland Press. 
Rice-Evans C.A., Dip lock A.T., Symons M.C. (1991) Techniques in free radical 
research. Amsterdam: Elsevier. 
Roberfroid M.，Calderon P.B. (1995) Free radicals and oxidation phenomena in 
biological systems. New York: Marcel Dekker. 
Sato S.，Tatsumi K.，Nishino T. (1991) A novel xanthine dehydrogenase inhibitor 
(BOF-4272). Adv Exp Med Biol 309A: 135-138 
1 5 0 
Sheu S.Y., Chiang H.C. (1997) Inhibition of xanthine oxidase by hydroxylated 
anthraquinones and related compounds. Anticancer Res 17: 3293-3297 
Shigematsu S.，Ishida S.，Kara M.，Takahashi N.，Yoshimatsu H., Sakata T.’ Korthuis 
RJ. (2003) Resveratrol, a red wine constituent polyphenol, prevents superoxide-
dependent inflammatory responses induced by ischemia/reperfusion, platelet-
activating factor, or oxidants. Free Radic Biol Med 34: 810-817 
Shin N.H.，Ryu S.Y., Choi E.J.，Kang S.H.，Chang I.M.’ Min K.R., Kim Y. (1998) 
Oxyresveratrol as the potent inhibitor on dopa oxidase activity of mushroom 
tyrosinase. Biochem Biophys Res Commun 243: 801-803 
Shviro Y.，Shaklai N. (1987) Glutathione as a scavenger of free hemin. A mechanism 
of preventing red cell membrane damage. Biochem Pharmacol 36: 3801-3807 
Silverman R.B. (2000) The organic chemistry of enzyme-catalyzed reactions. San 
Diego: Academic Press. 
Soszynski M., Bartosz G. (1997) Decrease in accessible thiols as an index of 
oxidative damage to membrane proteins. Free Radic Biol Med 23: 463-469. 
Stocker R. (1993) Natural antioxidants and atherosclerosis. Asia Pacific J Clin Nutr 2: 
15-20 
Stryer L. (1995) Biochemistry, ed. New York: W.H. Freeman. 
1 5 1 
Stupans I.，Ryan AJ. (1984) In vitro inhibition of 3-methylcholanthrene-induced rat 
hepatic aryl hydrocarbon hydroxylase by 8-acyl-7-hydroxycoumarins. Structure-
activity relationships and metabolite profiles. Biochem Pharmacol 33: 131-139 
Surgenor D.M. (1974) The red blood cell, Volume I ， e d . New York: Academic 
Press. 
Suzumura K.’ Yasuhara M.，Narita H. (1999) Superoxide anion scavenging properties 
offluvastatin and its metabolites. Chem Pharm Bull (Tokyo) 47: 1477-1480 
Takahashi H., Yamaguchi M. (1994) Activating effect of regucalcin on (Ca^ -^Mg "^^ )-
ATPase in rat liver plasma membranes: relation to sulfhydryl group. Mol Cell 
Biochem 136: 71-76 
Takahashi T.’ Morita K.，Akagi R.，Sassa S. (2004) Heme oxygenase-1: a novel 
therapeutic target in oxidative tissue injuries. Curr Med Chem 11: 1545-1561 
Tsutsumi Z.，Moriwaki Y., Takahashi S•，Ka T.，Yamamoto T. (2004) Oxidized low-
density lipoprotein autoantibodies in patients with primary gout: effect of urate-
lowering therapy. Clin Chim Acta 339: 117-122 
Waring W.S., Webb DJ.，Maxwell S.R. (2001) Systemic uric acid administration 
increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 
38: 365-371 
1 5 2 
Watanabe T.，Tawada Y.，Shigekawa M. (1988) Purification of cardiac (Na+,K+)-
activated adenosine triphosphatase from rat. Anal Biochem 175: 284-288 
World Health Organization (WHO). (1999) WHO monographs on selected medicinal 
plants, Volume I. Geneva: WHO. 
Wortmann R.L. (2002) Gout and hyperuricemia. Curr Opin Rheumatol 14: 281-286 
Wu Y.，Fisher W. (1944) Bi patterns. In Fratkin J. (Ed.). Practical therapeutics of 
traditional Chinese medicine: 254-264. Massachusetts: Paradigm Publications. 
Xia J., Browning J.D., O'Dell B丄.(1999) Decreased plasma membrane thiol 
concentration is associated with increased osmotic fragility of erythrocytes in zinc-
deficient rats. J Nutr 129: 814-819 
Xiao P., He L.Y., Wang L.W. (1984) Ethnopharmacologic study of Chinese rhubarb. 
J Ethnopharmacol 10: 275-293 
Yagi A., Kabash A., Okamura N.，Haraguchi H., Moustafa S.M., Khalifa T.L (2002) 
Antioxidant, free radical scavenging and anti-inflammatory effects of aloesin 
derivatives in Aloe vera. Planta Med 68: 957-960 
Yen G.C., Duh P.D., Chuang D.Y. (2000) Antioxidant activity of anthraquinones and 
anthrone. Food Chem 70: 437-441 
1 5 3 
Yokode M., Kita T. (1988) LDL isolation and copper-catalysed oxidation. In 
Taniguchi N.，Gutteridge J.M. (Ed.). Experimental protocols for reactive oxygen and 
nitrogen species: 149-151. New York: Oxford University Press. 
Yuan Z., Gao R. (1997) Anti-oxidant actions of anthraquinolines contained in Rheum. 
Pharm Pharmacol Lett 7: 9-12 
Zheng R丄.，Zheng T.S. (1992) Retardation of cell aging by lipid peroxidation. Mol 
Cell Biochem 115: 59-62 
Zhou C.X., Kong L.D., Ye W.C., Cheng C.H., Tan R.X. (2001) Inhibition of xanthine 
and monoamine oxidases by stilbenoids from Veratrum taliense. Planta Med 67: 158-
161 
Zhou C.X., Tanaka J., Cheng C.H., Higa T.，Tan R.X. (1999) Steroidal alkaloids and 
stilbenoids from Veratrum taliense. Planta Med 65: 480-482 
Zuckerman S.H., Bryan N. (1996) Inhibition of LDL oxidation and myeloperoxide 
dependent tyrosyl radical formation by the selective estrogen receptor modulator 
raloxifene (LY139481 HCL). Atherosclerosis 126: 65-75 
1 5 4 
• • 
. .
 . t 
• % 








. . . . , 乂 
• 〈 必 












 . , . •
 •




 J . 














 , . , ， ： - - 、 >
















. - . . . . . - : • — — . . ： ： • . . 
.....
 .-.
 r v n . . . . ; - ; . 
. V ? ,
 .
 ？ ” . 」 . J




 - A .
 . . .
 y , , ^
 , ； . .
 - r 
‘











































































 . . . . . ， . . 卞






 • : • .
 . . .
 .
 - . : 、 ‘ •
 .






 . . .
 f 
• .




 . I T
 '














 . , .
 :
 ,



















































 r . 
. -
 ， 















C U H K L i b r a r i e s 
mimmmi 
0 0 4 2 7 0 3 8 2 
